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DECONVOLUTE BRAIN TUMOR GENOMIC ALTERATIONS BASED ON DNA 
METHYLATION DATA 
Jie Yang, M.S. 
Advisory Professor: Erik Sulman, M.D. Ph.D. 
Molecular classification based on mutations, expression subtypes, and copy number 
variants has improved diagnosis and treatment decision-making for patients with brain tumors, 
particularly malignant gliomas. However, the association between epigenetic signature and 
genetic alterations is poorly understood. For example, mutation of isocitrate dehydrogenase (IDH) 
is associated with genome-wide hypermethylation of CpG islands in gliomas. But other subtype-
associated alterations, including telomerase reverse transcriptase (TERT) promoter mutation, 
alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation, chromosome 1p19q 
co-deletion (chr1p19q codel), and gene expression subtypes, have yet to be associated with any 
epigenetic signature. Therefore, we hypothesized that DNA methylation signatures can classify 
gliomas based on these alterations and give insight into subgroup characteristics. Machine 
learning models, including elastic net and random forest, were used to predict somatic mutations 
of IDH, TERTp, and ATRX, chr1p19q codel, and gene expression subtype of gliomas. Data from 
the NOA-04 randomized phase III trial were used for external validation. In total, 926 cases from 
The Cancer Genome Atlas were included in this study. Prediction accuracies for IDH, TERTp, 
and ATRX mutations, and chr1p19q codel were 100%, 98.3%, 90.48%, and 99.21%, respectively 
in test set. Accuracy for gene expression subtype prediction was 72.2%. The methylation-based 
prediction models for both ATRX and chr1p19q codel statuses proved superior to conventional 
assays for these biomarkers. Similarly, characteristic alterations associated with gene expression 
subtypes were better discriminated using methylation compared to transcriptome-based 
classification. DNA methylation signatures accurately predicted somatic alterations and improved 
over existing classifiers. The established Unified Diagnostic Pipeline (UniD) is a rapid and cost-
effective diagnostic platform of genomic alterations and gene expression subtypes at initial 
clinical diagnosis and improves over individual assays currently in clinical use. The significant 
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relationship between genetic alterations and epigenetic signatures indicates the broad 
applicability of our approach to other malignancies. 
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A glioma is a type of brain tumor that originates in the glial cells and is the most 
commonly seen malignant brain tumor. Gliomas are classified into four different grades 
according to their malignancy, growth speed, cell infiltration, and aggressiveness. 
Grade IV gliomas are also called glioblastomas (GBMs) and are lethal in almost every 
patient. The standard care for glioma patients is surgery followed with or without 
radiation/chemotherapy. However, due to limited understandings of this devastating 
tumor, there is no efficient treatment for it and the prognosis is still very poor. In recent 
years scientists have been able to gain more insight about gliomas’ molecular features 
because of the development of molecular biotechnology. 
Glioma classification based on DNA methylation and gene expression profiles 
helps identify subgroups with characteristic molecular features. In addition to 
classification, specific genomic alterations play an important role in tumor initiation, 
progression, and prognosis. For example, somatic mutations of the gene isocitrate 
dehydrogenase (IDH), telomerase reverse transcriptase promoter (TERTp), and alpha 
thalassemia/mental retardation syndrome X-linked (ATRX) and chromosome 1p19q co-
deletion (chr1p19q codel). It has been found that IDH mutation shows a strong 
relationship with a subgroup of GBM with genome-wide hypermethylation. Meanwhile, 
DNA methylation profile is believed to reflect the tumor cell of origins. Therefore, I 
decided to investigate the potential relationships between DNA methylation profiles 
and known somatic genomic alterations. My study will not only lead to insights about 
gliomas’ genomic alterations but will also allow multiple genomic alteration status to 
be determined with only one simple assay. 
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The first chapter introduces the basic information about gliomas and the related 
molecular information, DNA methylation platform and microarray data, and machine 
learning models and techniques used in the study. The second chapter is focused on 
the methods and results of building predictive models for binary genomic alterations 
using DNA methylation data. The third chapter introduces the methods and results of 
building predictive models for gene expression subtypes using DNA methylation data. 
The last chapter includes this study’s conclusions, discussions, limitations, and future 
directions. My studies of the relationship of DNA methylation and somatic genomic 
alterations show that DNA methylation can accurately predict genomic alterations in 
gliomas and reveal enrichment of characteristic genomic alterations. Furthermore, in 
addition to all the known advantages, methylation microarray holds the potential to 
expand DNA methylation biomarker predictive signatures in gliomas and other types 
of cancer.  
1.1 Brain tumor  
A brain tumor is a tumor grown in the brain and may be benign or malignant. Brain tumors 
can also be categorized as primary brain tumors and metastatic brain tumors based on their 
origins. A primary brain tumor is a tumor that originates from brain tissue, and a metastatic brain 
tumor usually begins in other parts of the body and later migrates to the brain through the blood. 
Most metastatic brain tumors originate from breast cancer, lung cancer, kidney cancer, or 
melanoma. The diagnosis of a brain tumor requires a combination of sophisticated imaging tools 
and determination of tumor biopsy histopathology. After diagnosis, patients with brain tumors are 
treated with surgery, and/or radio- or chemotherapy. 
1.1.1 Glioma introduction 
A glioma is a type of brain tumor that develops from glial cells. Glial cells are the most 
abundant type of cell in the brain and can provide support, nutrition, and energy to the neurons. 
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There are different types of glia cells including astrocyte, oligodendrocyte, microglia, and others 
in the peripheral nervous system.  
 Gliomas are the most commonly seen primary malignant brain tumor in adults. Based on 
World Health Organization (WHO) classification of tumors of the central nervous system (CNS 
(1)), there are four grades (grade I to IV) based on their malignancy, growth speed, tumor cell 
infiltration, and aggressiveness (Table 1). Grade I gliomas are called pilocytic astrocytoma and 
often occur in children. This type of tumor usually grows slowly and is relatively benign. Grade II 
gliomas include astrocytoma, oligodendroglioma, and mixed oligoastrocytoma. Grade III gliomas 
include anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic mixed 
oligoastrocytoma. The highest-grade glioma, grade IV, is usually called GBM and is the most 
common and malignant type of brain tumor. Patients with GBM usually die within one year after 
diagnosis (2). Low-grade gliomas (LGGs, including grades I and II) usually are less malignant 
and aggressive and have better prognoses than high-grade gliomas (grade III and IV). However, 
LGGs have a high probability of evolving into high-grade gliomas. 
Table 1: Glioma grading 
 
Epidemiological research about brain and other CNS tumors reported 392982 incidences 
between 2011 and 2015 (3), 23.8% of which were gliomas. Among all gliomas, about 80% are 
malignant and 61.7% are GBMs. The median age of diagnosis with glioma is 57 years old. 
Gliomas are observed more in male (56.1%), white (88%) patients. Among all malignant brain 
and CNS tumors, GBM has the highest rate of 3.21 per 100,000 and the five-year survival rate 
Grade benign/malignant growth rate major subtypes 
I benign slow pilocytic astrocytoma 
II malignant medium astrocytoma, oligodendroglioma, mixed oligoastrocytoma 
III malignant medium 
anaplastic astrocytoma, anaplastic 
oligodendroglioma, anaplastic mixed 
oligoastrocytoma 
IV malignant fast glioblastoma 
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is about 5.6% for all ages. Table 2 shows that the five-year survival rate decreases significantly 
as the grade of glioma increases. 
Table 2: one-year and five-year survival rate (%) and 95% CI* (months) for glioma by grading 
* CI: confidence interval 
Note: Data summarized from Central Brain Tumor Registry of the United States (CBTRUS) 2018 
version (3) 
 
Current understandings of tumor initiation, evolution, and progression are poor. In recent 
years, many researchers have shown that high-throughput genomic data may help to understand 
this devastating tumor better. Several predictive biomarkers have been discovered, such as IDH 
mutation status, which is positively associated with younger age and longer survival time; 
chr1p19q codel, which is prognostic of improved survival and predictive of response to 
chemotherapy (1, 4); and O-6-methylguanine-DNA methyltransferase (MGMT) methylation 
status (5), which is beneficial for patients’ treatment with alkylating chemotherapy such as 
carmustine or temozolomide. The first two biomarkers, IDH mutation and chr1p19q codel have 
been included in the recent revisions of WHO diagnostic criteria for gliomas. In addition, TERTp 
mutation (6) and ATRX mutation are mutually exclusive but both are functionally correlated with 
telomere length maintenance (7, 8).  
GBM has also been classified into three subtypes base on characteristic gene expression 
signatures called classical (CL), proneural (PN), and mesenchymal (MES) (9). CL GBMs 
frequently have epidermal growth factor receptor (EGFR) amplification and higher expression 
grade subtype 
one-year five-year 
survival rate 95% CI* survival rate 95% CI* 
I pilocytic astrocytoma 97.9 97.4-98.3 94.1 93.2-94.8 
II 
 
astrocytoma 74.9 73.8-76.0 50.4 49.0-51.7 
oligodendroglioma 94.7 93.8-95.4 81.6 20.1-83.1 
oligoastrocytoma 88.7 87.3-90.0 63.7 61.4-65.8 
III 
anaplastic astrocytoma 65.3 63.9-66.8 30 28.4-31.5 
anaplastic 
oligodendroglioma 84.4 82.4-86.2 57.6 54.7-60.4 
IV glioblastoma 40.2 39.7-40.7 5.6 5.3-5.8 
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while MES GBMs have high rates of neurofibromin 1 (NF1) loss function mutation (9). GBMs 
have distinguished copy number alterations (CNAs) compared to other types of cancer. For 
example, GBM samples have characteristic chromosome 7 amplifications and chromosome 10 
deletions. In the following subsections, those key genetic alterations are introduced in detail. 
1.1.2 Molecular Classification 
The Cancer Genome Atlas (TCGA) is a landmark cancer-related genomic program 
initiated in 2006. It has molecularly characterized over 20,000 primary cancer samples spanning 
33 cancer types. GBM was the first systematically investigated cancer type in this program and 
then the program expanded to other LGGs. In this project, glioma samples were well-
characterized in many genomic aspects, including messenger RNA (mRNA) gene expression 
level, DNA sequencing, copy number variations, DNA methylation profile, and others. This 
provided me the chance to study it as a whole set, therefore, different molecular classifications 
were proposed. I will give a brief introduction of some important classifications according to 
published papers.  
1.1.2.1 Gene expression classification of GBM 
In 2006, Phillips et al. (10) published the first high-impact paper about the gene 
expression subclasses of high-grade astrocytoma in Cancer Cell. They studied 76 newly 
diagnosed high-grade astrocytoma patients with DNA microarray gene expression data and 
clustered them into three subclasses: PN, MES and proliferation. These three subclasses of 
samples show differences in tumor grade, patient age, proliferation, angiogenesis, neurogenesis, 
copy number variations, and signaling pathway activation status. By comparing the paired 
primary and recurrent gliomas, recurrent samples were found to shift towards the mesenchymal 
phenotype and showed frequent loss of oligodendrocyte transcription factor (OLIG2) expression 
and chitinase-3-like protein 1 (CHI3L1) upregulation. More importantly, the authors tried to 
explain the progression process between these three subclasses in their paper. 
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In 2010, Verhaak et al. (11) published a paper about the gene expression subtypes of 
GBM using a larger data set from TCGA and integrating multiple genomic characterizations. In 
this paper, the authors classified GBM into four subtypes: PN, MES, neural, and CL. Each 
subtype was characterized in terms of gene expression level, clinical phenotypes, copy number 
variations, gene mutation rate, and relationship with cell types. Among them, some genes were 
well characterized for each subtype, including tumor protein p53 (TP53), IDH1, platelet-derived 
growth factor receptor alpha (PDGFRA), EGFR, NF1, and cyclin-dependent kinase inhibitor 2A 
(CDKN2A; Table 3). In short, PN subtype samples were characterized by high IDH mutation 
rates and high expression and amplification of PDGFRA. Neural subtype samples showed high 
expression of neuron marker genes, including neurofilament protein, light polypeptide (NEFL), 
gamma-aminobutyric acid receptor alpha 1 (GABRA1), synaptotagmin 1 (SYT1), and so on. MES 
subtype samples showed high mutation rates and low expression of NF1, focal hemizygous 
deletions at chr17q11.2, high nuclear factor-kB (NF-kB) pathway expression, and poor prognosis. 
CL GBM showed frequent chr10 loss and chr7 amplification, high EGFR expression and 
amplification, homozygous CDKN2A deletion, and high expression of Notch and Sonic hedgehog 
signaling pathway. Though these four subtypes did not show indications of a strong prognosis, 
they provided a systematic understanding in terms of mRNA expression and correlation of the 
subtypes to other genomic features. 
Table 3: Characteristics of gene expression subtypes by 2010 Cancer Cell paper 
Note: Information summarized from Verhaak et al. (11)  
 
Genomic feature Proneural Neural Mesenchymal Classical 
median diagnostic age 51.8 63.8 57.7 55.7 
IDH mutation rate 30.0% (11/37) 5% (1/19) 0% (0/38) 0% (0/22) 
TP53 mutation rate 54% (20/37) 21% (4/19) 32% (12/38) 0% (0/22) 
PDGFRA mutation rate 11% (4/37) 0% (0/19) 0% (0/38) 0% (0/22) 
EGFR mutation rate 16% (6/37) 26% (5/19) 5% (2/38) 32% (7/22) 
NF1 mutation rate 5% (2/37) 16% (3/19) 37% (14/38) 5% (1/22) 
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In 2017, an improved gene expression-based classification system was proposed by 
Wang et al. (9) by using the single cell sequencing technology. With about 600 single glioma 
cells RNA sequencing data and glioma sphere-forming cell (GSC) RNA sequencing data, Wang 
et al. identified a set of genes that are uniquely expressed by glioma cells rather than tumor-
associated host cells. With those gliomas’ intrinsically expressed genes, the authors identified 
three gene expression subtypes within IDH-wild type GBMs: PN, MES, and CL. The subtype 
neural was excluded because its signals come from neurons. Moreover, a simplicity score was 
created to measure the intratumor heterogeneity by multi-subtype activation, which means one 
glioma sample with multiple gene expression subtypes is activated. Furthermore, this paper 
showed that these three different subtypes can differentially activate the immune environment, 
as mainly happens between the MES and non-MES samples. As reported before, MES samples 
have worse prognoses and lower tumor purity compared to non-MES samples. 
1.1.2.2 DNA methylation classification 
In 2010, TCGA project published a paper about GBM classification (12) using DNA 
microarray data. In this classification, a small subset of GBMs (about 5 to 10%) showed 
characteristics that distinguish them from other GBMs, such as overall hypermethylation, high 
IDH1 and IDH2 mutation rate, younger diagnostic age, and significantly longer survival time; 
these were named glioblastoma CpG island methylator phenotype (G-CIMP). CIMP, as a 
phenotype characterized as genome-wide gene promoter region hypermethylation, was first 
identified in colorectal cancer by Toyota et al. (13). They found methylation of cancer-specific 
clones exclusively existed in a subset of colorectal cancer. This kind of epigenetic aberration may 
be associated with tumor suppressor genes and can be used as biomarker. The relationship 
between G-CIMP and IDH mutation is further explained in the following IDH mutation section 
1.1.3.1. 
In 2018, a DNA methylation-based classification of all CNS tumors was published in 
Nature by Capper et al. (14). In this study, the researchers applied unsupervised analysis using 
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Illumina HumanMethylation450 (HM450k) DNA methylation data for over 100 CNS tumor types 
and then built a random forest classifier which could be used to classify new sample data (Figure 
1). Results of this study are useful to help pathologists provide potential diagnoses in challenging 
cases and to help further avoid individual subjective effects of diagnoses. However, it is worth 
noting that Capper et al. did not classify samples using any specific biomarkers but using overall 
methylation profiles. Moreover, they covered all CNS tumor types, not just gliomas. These are 
the key differences between this project and my proposed project.  
 
Figure 1: Establishing the DNA methylation-based CNS tumor reference cohort. 
A Overview of the 82 CNS tumor methylation classes and nine control tissue methylation classes 
of the reference cohort. The methylation classes are grouped by histology and color-coded. 
Category 1 methylation classes are equivalent to a WHO entity, category 2 methylation classes 
are a subgroup of a WHO entity, category 3 methylation classes are not equivalent to a unique 
WHO entity with combining of WHO grades, category 4 methylation classes are not equivalent 
to a unique WHO entity with combining of WHO entities, and category 5 methylation classes are 
not recognized as a WHO entity. Full names and further details of the 91 classes are included 
in Supplementary Table 1. Embryonal tumors, shades of blue; glioblastomas, shades of green; 
other gliomas, shades of violet; ependymomas, shades of red; glio-neuronal tumors, shades of 
orange; IDH-mutated gliomas, shades of yellow; choroid plexus tumors, shades of brown; pineal 
region tumors, shades of mint green; melanocytic tumors, shades of dark blue; sellar region 
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tumors, shades of cyan; mesenchymal tumors, shades of pink; nerve tumors, shades of beige; 
haematopoietic tumors, shades of dark purple; control tissues: shades of grey. B Unsupervised 
clustering of reference cohort samples (n = 2,801) using t-SNE dimensionality reduction. 
Individual samples are color-coded in the respective class color (n = 91) and labelled with the 
class abbreviation. The color code and abbreviations are identical to A. 
Note: Figure and legend from Capper, David, et al. "DNA methylation-based classification of 
central nervous system tumours." Nature 555.7697 (2018): 469. (14) with license number 
4667250031818. 
 
1.1.2.3 Diffuse glioma subtype classification 
In 2016, TCGA consolidated all LGG and GBM samples (n = 1,122) and identified seven 
different subtypes with distinct biological and clinical characteristics (15). This classification no 
longer followed the traditional pathohistological grading rules but mixed LGG and GBM samples 
under the name diffuse glioma. All diffuse gliomas were first classified in IDH mutant or IDH wild 
type subgroups. Within the IDH-mutant subgroup, gliomas were further classified into G-CIMP-
low, G-CIMP-high, and chr1p19q codel subgroup; within the IDH wild-type subgroup, gliomas 
were further classified into CL-like, MES-like, LGm6-GBM, and PA-like subgroups. This 
classification emphasized the effect of IDH mutation, which is believed to be an early event in 
tumor initiation and progress, and further showed the genomic similarity between IDH mutant 
LGG and GBM. In other words, according to the pathohistological grading, LGG and GBM are 
different grades of glioma. However, in terms of genetic similarity, they actually belong to the 
same subtype or may have the same origin if they harbor IDH mutation. 
1.1.3 Somatic mutation 
Generally, cancer is recognized as a genetic disease and genetic alterations and 
epigenetic alterations play important roles in cancer initiation, evolution, and prognosis. Genetic 
alterations usually refer to DNA sequence changes, or mutations. Mutations can be categorized 
into two different types: somatic and germline mutation. Somatic mutations usually occur in a 
single body cell and cannot be passed on to offspring, while germline mutations usually occur in 
gametes and can be passed on to offspring. A typical example of germline mutation is 
retinoblastoma, which mainly affects young children. Almost half of the retinoblastoma patients 
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have inherited mutated retinoblastoma protein 1 (RB1), which is a tumor suppressor gene, from 
their parents. In my dissertation, I will focus on the key somatic mutations for GBM, including IDH, 
TERT, and ATRX mutation. 
1.1.3.1 Isocitrate dehydrogenase (IDH) 
IDH is a family of genes which encode enzymes that can catalyze isocitrate to a-
ketoglutarate (aKG). Three genes belong to this family: IDH1 on chr2q32; IDH2 on chr15q21; 
and IDH3 on chr15q25. As shown in Figure 2, IDH1 located in the cytosol while IDH2 and IDH3 
are located in mitochondria. To catalyze the conversion of isocitrate to aKG, IDH1 and IDH2 
need nicotinamide adenine dinucleotide phosphate (NADP+) and IDH3 needs nicotinamide 
adenine dinucleotide (NAD+) as cofactors and therefore is a major pathway to generate NADPH 
and NADH.  
 
Figure 2: Wild-type IDH and mutant IDH functioning in cell.  
 
For IDH loss function mutation, all mutations can be mapped to the key residue within the 
active site, which is critical for isocitrate binding, especially of codon R132 of IDH1, and codons 
R172 and R140 of IDH2. However, missense substitutions are quite flexible, which leads to the 
assumption that the location is more important than the substituted codons. The mutant IDH can 
lead to the decreased production of aKG and increased the production of 2- hydroxyglutarate (2-
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converted back to aKG through D-2-hydroxyglutarate dehydrogenase, mitochondrial (D2HGDH). 
However, the mutant IDH enzymes can convert aKG to 2-HG. It has been reported by Xu et al. 
(16) that 2-HG is a competitive inhibitor of aKG dependent dioxygenases, which include the 
histone demethylases and ten-eleven translocation (TET) family of 5-methlycytosine 
hydroxylases. Therefore, the accumulation of 2-HG can result in genome-wide DNA methylation 
and histone profile change (mainly increasing) and can block cellular differentiation, which is 
associated with tumor initiation and progression. Therefore, IDH mutation has been proposed as 
a potential target for cancer therapy. In fact, IDH mutation inhibitors such as AG-221 (17) (mutant 
IDH2 inhibitor), AG-120 (18) (mutant IDH1 inhibitor), and AG-881 (mutant IDH1/IDH2 inhibitor) 
have been under evaluation and the preliminary data show promising results. 
IDH gene mutations have been observed in many different cancer types, including acute 
myeloid leukemia (AML), GBM, intrahepatic cholangiocarcinoma, and others. Both IDH1 and 
IDH2 mutations are found related to glioma, and the most common mutation happens in IDH1 at 
amino acid residue 132, which results in arginine being replaced with histidine (R132H). About 
80% of LGGs and secondary GBMs are found to harbor IDH mutation, while only a small portion 
(about 5 to 10%) of primary GBMs have IDH mutation. This group of GBMs with IDH mutation 
show upregulated methylation profiles (Figure 3), younger age at diagnosis, longer survival time, 
and the majority of them are harboring IDH mutations. GBMs belong to this subgroup were 
named as G-CIMP samples. Also, this subgroup of primary GBM samples has been found 
showing PN subtype genetic characterization, which is more similar to LGG samples than typical 
GBM samples. The causal relation between IDH mutation and G-CIMP has been proven by Sevin 
et al. (19). By constructing isogenic astrocytes expressing either IDH R132H mutation, wild type 
IDH, or neither, the 2-HG production level and methylome profile were compared. It was found 
that IDH R132H mutation astrocytes show high expressed 2-HG and overall methylation level 
increased by cell passages.  
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Figure 3: Unsupervised clustering analysis of GBM DNA methylation profile.  
One-dimensional hierarchical clustering of the same 1503 most variant probes. Each row 
represents a probe; each column represents a sample. The level of DNA methylation (beta value) 
for each probe, in each sample, is represented with a color scale as shown in the legend; white 
indicates missing data. M.SssI-treated DNA (n = 2), WGA-DNA (n = 2), and normal brain (n = 4) 
samples are included in the heatmap but did not contribute to the unsupervised clustering. The 
probes in the eight control samples are listed in the same order as the y axis of the GBM sample 
heatmap.  
Note: Figure and legend from Noushmehr, Houtan, et al. "Identification of a CpG island 
methylator phenotype that defines a distinct subgroup of glioma." Cancer cell 17.5 (2010): 510-
522. (20) with license number 4667300694903. 
 
IDH mutation has been used as a prognostic biomarker for GBMs that show better 
survival rates. Many hypotheses have been proposed to explain these better prognoses. For 
example, it has been suggested that cancer cells with reduced NADPH production are more 
vulnerable to irradiation and chemotherapy because of their decreased capacity to scavenge 
reactive oxygen species generated during irradiation and chemotherapy (21). Moreover, IDH 
mutation may lead to a suppressed immune response to glioma through down-regulated 
leukocyte chemotaxis, which in turn reduces the aggressiveness of tumors and leads to longer 
survival (22). Moreover, lower immune cell infiltration in IDH mutant glioma may also contribute. 
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1.1.3.2 Telomerase reverse transcriptase (TERT) 
Telomere is a special heterochromatin structure located at the end of the linear 
chromosome. It consists of high GC DNA sequences and is enclosed by specific proteins. During 
the cell division process, the telomere loses some base pairs because the RNA primer is involved 
in the DNA replication process. The RNA primer will bind with DNA sequences, but this region 
cannot be replicated. As the cell division progresses, telomere gets shorter and shorter, and once 
it reaches a certain length, the cell will start apoptosis or stop further division. Telomere works 
like a clock to maintain the length and stability of chromosomes, self-renewal, and proliferation. 
Two major mechanisms are involved in telomere length maintenance in cancer: 
telomerase activation, or upregulation (85%-90%) and the alternative lengthening of telomeres 
(ALT) pathway. These two mechanisms are mutually exclusive in most situations but may coexist 
in rare situations, and the switch between telomerase upregulation and ALT has also been 
observed. Two major components make up the telomerase enzyme: hTR, the RNA component, 
which provides the template for DNA synthesis, and hTERT, the protein that catalyzes 
components and adds the new DNA segments to the ends of chromosomes. hTR is encoded by 
the gene telomerase RNA component (TERC), located on chr3q26, and hTERT is encoded by 
the gene TERT, located on chr5p13. Both components are essential for telomere maintenance. 
TERT is usually silenced in normal cells but is activated in cancer cells. Different mechanisms 
can activate or upregulate the hTERT expression including promoter mutation, alteration in 
alternative splicing of pre-mRNA, gene amplification, epigenetic changes, and others (23). I will 
focus on TERTp mutation in this section.  
TERTp mutation has been observed in more than 50 cancer types and is a major 
mechanism to activate the telomerase in cancer cells. For example, the TERTp mutation rate is 
43% in CNS tumors (~80% for GBM), 59% in bladder cancer, and 29% in skin cancer (~70% in 
melanoma; (24). Two TERTp mutation hotspots have been reported: C228T and C250T, which 
are located -124bp and -146bp upstream from the TERT transcriptional start site (TSS). Studies 
suggested that promoter region mutation can lead to the change of binding preferences and 
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adding additional binding sites (Figure 4) (23). The telomerase expressions are higher in cancer 
samples with TERTp mutation compared to TERTp wild type. 
In general, TERTp mutation has been observed to be associated with decreased overall 
survival rates. However, the coexistence with other prognostic biomarkers, such as IDH, MGMT, 
and chr1p19q codel, should be considered for GBMs when evaluating the prognostic effects. The 
molecular classification of gliomas according to TERTp mutation is useful and powerful. Anti-
telomerase therapeutics focus on inducing apoptosis and cell death in cancer cells while 
minimizing the risk of telomere shortening in normal cells. Different approaches have been 
adopted such as hTERT- or hTR-targeted antisense oligonucleotides and small molecule 
inhibitors (23). 
 
Figure 4: TERT transcription and promoter mutations. 
Two TERTp mutation hotspots are showed in the figure: C250T and C228T. The transcription is 
regulated by transcription factors. TERTp mutations create E26 transformation-specific/ternary 
complex factor (ETS/TCF) binding motifs. Then more transcription factors can bind to their 
respective sites and promote TERT transcription.  
 
1.1.3.3 Alpha thalassemia/mental retardation syndrome X-linked (ATRX) 
Other than telomerase, ALT is another major mechanism to maintain telomere length in 
cancer cells. It is hypothesized that the ALT process involves homologous recombination (HR)-
mediated DNA replication; however, the precise mechanism is still less understood (Figure 5). 
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abundant extrachromosomal telomeric repeat DNA (ECTR), high levels of telomere sister 
chromatid exchanges (t-SCES), and ALT-associated promyelocytic leukemia (PML) bodies 
(APBs) that have a specialized telomeric DNA nuclear structure (25). Though TP53 inactivation 
has been widely observed in many cancer types, it is believed to be necessary for ALT cancer 
cells (26). About 10% to 15% of human cancers utilize the ALT rather than the telomerase-
dependent mechanism to maintain their telomere length. Moreover, studies have reported that 
mesenchymal origin cancers are more likely to utilize the ALT mechanism and are less likely to 
express telomerase (27, 28).  
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Figure 5 Repair of DNA double-strand breaks by DSBR and SDSA.  
Double-strand breaks (DSBs) can be repaired by several HR-mediated pathways, including 
double-strand break repair (DSBR) and synthesis-dependent strand annealing (SDSA). A In both 
pathways, repair is initiated by resection of a DSB to provide 3′ single-stranded DNA (ssDNA) 
overhangs. Strand invasion by these 3′ ssDNA overhangs into a homologous sequence is 
followed by DNA synthesis at the invading end. B After strand invasion and synthesis, the second 
DSB end can be captured to form an intermediate with two Holliday junctions (HJs). After gap-
repair DNA synthesis and ligation, the structure is resolved at the HJs in a non-crossover (black 
arrow heads at both HJs) or crossover mode (green arrow heads at one HJ and black arrow 
heads at the other HJ). C Alternatively, the reaction can proceed to SDSA by strand displacement, 
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annealing of the extended single-strand end to the ssDNA on the other break end, followed by 
gap-filling DNA synthesis and ligation. The repair product from SDSA is always non-crossover. 
Note: Figure and legend are from Sung, Patrick, and Hannah Klein. "Mechanism of homologous 
recombination: mediators and helicases take on regulatory functions." Nature reviews Molecular 
cell biology 7.10 (2006): 739. (29) with license number 4667681409176. 
 
Mutations of ATRX, located on chrXq21, or death-domain associated protein (DAXX), 
located on chr6p21, have been frequently observed in cancer cells with the ALT phenotype. The 
gene ATRX encodes SWItch/Sucrose Non-Fermentable (SWI/SNF) like chromatin remodeling 
protein and therefore have the chromatin remodeling function (30): with the ATRX-DNMT3-
DNMT3L (ADD) domain and HP1a, ATRX can bind and regulate genomic regions enriched for 
H3K9me3 (31). It can also regulate transcription by recruiting enhancer of zeste 2 polycomb 
repressive complex 2 subunit (EZH2) to deposit H3K27me3. By binding DNA through its 
transcription regulatory protein SNF2 N-terminal helicase domain, ATRX can resolve tandem 
repeats and further promote transcription at the a-globin locus. ATRX can deposit H3.3 with 
DAXX to repetitive regions and negatively regulate macroH2A (mH2a) deposition at the a-globin 
locus and telomeres. DAXX is a highly conserved protein associated with nuclear and 
cytoplasmic events during apoptosis. ATRX/DAXX complexes function as histone chaperone to 
deposit the histone variant H3.3 to repetitive heterochromatin. It has been proposed that the loss 
function mutations of either ATRX or DAXX coexist with IDH and TP53 mutation in gliomas and 
are mutually exclusive with far upstream element binding protein 1 (FUBP1), capicua 
transcriptional repressor (CIC) and chr1p19q codel. 
Many theories have been proposed to explain how the loss function of ATRX mutation 
affects the ALT. Clynes et al. (32) proposed that with loss function mutation of ATRX or DAXX, 
the H3.3 cannot be deposited at the G-rich repeats in the telomere region, which leads to the 
formation of a G4 structure, replication fork stalling, and the HR of telomeres and finally the ALT. 
O’Sullivan et al. (33) proposed that ALT depends on the replicative stress by ATR 
serine/threonine kinase (ATR) and that ATRX can recognize G-quadruplexes (G4) structure and 
prevent replicative stress. Therefore, ATRX loss function is required for cancer cells to maintain 
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the ALT phenotype. G4 structure is a secondary DNA structure that can lead to replicative stress 
or block transcriptional processes, which is formed by the G-rich tandem repeats upstream of the 
alpha-globin genes. In summary, the loss function of ATRX mutation is a prerequisite of the ALT 
mechanism. 
1.1.4 Copy number variation (CNV) 
Copy number variation is another key genomic feature of cancer cells and involves gain 
or loss of genomic DNA. Currently, the most commonly used high-throughput technology to 
measure the copy number variation is the single nucleotide polymorphism (SNP)-array, for 
example, the Affymetrix 6.0 platform (SNP6) has been used in TCGA project. On this microarray, 
probes are designed to test the genotype of the SNP and the probe signal intensities are used 
to calculate the copy number. It is assumed that the majority of the genome is diploid and it is 
used as the baseline for signal intensities normalization. For example, if a certain genome region 
has amplification, then all probes located within this region are expected to have higher signal 
intensities no matter which genotype they are and vice versa. After data cleaning and noise 
reduction, circular binary segmentation (CBS) (34) is used to call the copy number. This method 
evolved from binary segmentation, which only considers one change-point at a time, while the 
CBS considers two change-points. Assuming the arc from i+1 to j and its complement have 
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The null hypothesis is rejected if the statistic exceeds the critical value based on the null 
hypothesis and the critical value can be computed using Monte Carlo simulation or the 
approximation of tail probability when 𝑋" follows normal distribution. This procedure is applied 
recursively to search for all copy number breakpoints. 
The role of CNV as a risk factor for cancer is underestimated. The changes of copy 
number are commonly associated with the deletion of tumor suppressor genes or amplification 
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of oncogenes. For example, CL GBM has its special CNAs, which are characterized as chr7 
amplifications and chr10 deletions involving the change of EGFR and phosphatase and tensin 
homolog (PTEN). 
1.1.4.1 Chromosome 1p19q co-deletion (chr1p19 codel) 
A subgroup of IDH mutant gliomas show chr1p19q codel: the complete deletion of both 
the short arm of chr1 and the long arm of chr19. This genomic feature has nearly always been 
observed only in oligodendroglioma. The loss of one chromosome arm each in chr1 and chr19 
leads to the loss of heterozygosity (LOH). Chr1p19q codel is caused by an unbalanced whole-
arm translocation between chr1 and chr19, which happens in the early stage of cancer initiation. 
It usually coexists with IDH, TERTp, CIC and FUBP1 mutation and is mutually exclusive to TP53 
and ATRX mutation, except few rare cases. Though the reason why this specific deletion 
happens is unknown, it is an independent prognostic biomarker associated with better survival 
durations. Studies have shown that patients with IDH mutation and chr1p19q codel have a 
median overall length of survival of 8.0 years, while patients with IDH mutation and chr1p19q 
intact have a median length of survival of 6.3 years. In addition to its prognostic value, chr1p19q 
codel can also be used to predict the anaplastic oligodendrogliomas chemotherapy response. 
Randomized controlled clinical trials comparing the procarbazine/lomustine/vincristine (PCV) 
chemotherapy plus radiotherapy to radiotherapy alone have shown survival benefits for first-line 
chemotherapy in oligodendroglioma with chr1p19q codel (35, 36). With all these clinical values, 
chr1p19q codel has been included in the new WHO classification criteria. There are many 
different methods to detect the chr1p19q codel and fluorescent in situ hybridization (FISH) is one 
of the most widely-used methods. With the current high-throughput copy number evaluation 
methods available, chr1p19q codel can also be identified by checking the chromosome arm-level 
copy number alterations. 
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1.1.4.2 Other genomic features 
Genomic alterations, including mutation and copy number variation (CNV), are essential 
components in cancer etiology and progression and have been used for cancer diagnosis, 
classification, and as therapeutic targets. Epigenetic disruptions can interact with genetic 
alterations and contribute to abnormal cancer genomes. For example, tumor suppressor gene 
inactivation by epigenetic silencing is typically mutually exclusive of gene inactivation by mutation 
or deletion as exemplified by cyclin dependent kinase inhibitor 2A (CDKN2A) in lung squamous 
cell carcinoma (37) and breast cancer 1, early onset (BRCA1) in breast and ovarian cancer (38). 
In addition to single gene suppression, CIMP is another known association between somatic 
mutation and epigenetic signature that usually presents as hypermethylation within CpG site-
enriched regions, such as gene promoters. The first identified CIMP was in colorectal cancer (13) 
and the CIMP-high subgroup has been associated with mutation of v-raf murine sarcoma viral 
oncogene homolog B at V600 (BRAFV600E; (39), though the molecular mechanism is still unclear. 
The CIMP subgroup has also been identified in many other tumors (40, 41) (42), including GBM 
(12). G-CIMP patients show a strong association with IDH1 and IDH2 mutation and demonstrate 
longer survival compared to patients with non-G-CIMP tumors. 
1.1.4.3 MGMT promoter methylation 
The MGMT gene is located on chromosome 10q26.3 and encodes the DNA repair protein, 
which is involved in cellular defense against mutagenesis and toxicity from alkylating agents. The 
protein can transfer the methyl group from O6-alkylguanine to its own molecule, thus enhancing 
the fatal effects of alkylating agents. In contrast, defective MGMT will cause the base mis-
repairing and mismatch repair failure during DNA replication and finally lead to cell cycle arrest 
and apoptosis. Therefore, MGMT promoter methylation will lead to decreased level of functional 
MGMT protein and inadequate repair of DNA alkylation during chemotherapy with an alkylating 
agent. 
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About 30 to 50% GBM shows MGMT promoter methylation and it can be used as an 
efficient biomarker for alkylating chemotherapy response prediction, including temozolomide 
(TMZ). Patients who are treated with TMZ and with MGMT promoter methylation have longer 
survival times compared to patients who are treated with TMZ without MGMT promoter 
methylation (5). In addition to this predictive value, MGMT promoter methylation also has 
prognostic value: patients with MGMT promoter methylation have better survival rates regardless 
of whether they are treated with TMZ and radiation or radiation alone (43, 44). The most widely 
used methods to measure MGMT promoter methylation are the methylation-specific PCR (MS-
PCR; (45) and the methylation sensitive-quantitative locked nucleic acid PCR (MS-qLNAPCR). 
With DNA methylation microarray data, Bady et al. (46) built a logistic regression model (MGMT-
STP27) to predict MGMT promoter methylation status using two probes available on the 
BeadChip. 
1.2 Epigenetics and DNA methylation 
Epigenetics play a crucial role in cancer (47, 48) and lead to extensive reprogramming of 
cancer mechanisms through DNA methylation, histone variation (49), and noncoding RNA (50). 
As one of the most well-known epigenetic mechanisms, DNA methylation is a stable feature and 
can reflect both inter- and intratumor heterogeneity. It has been used to classify different types 
of tumors (13, 39, 51-53). For example, the recently published DNA methylation-based 
histopathological classification of CNS tumors (14) has challenged the conventional histologic 
classification and tumor grading. DNA methylation also provides clarity in unknown primary tumor 
classification (54). Another important application of DNA methylation is developing predictive and 
prognostic biomarkers (55), such as for tumor recurrence (56), treatment response and patient 
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1.2.1 DNA methylation 
1.2.1.1 DNA methylation definition and types 
DNA methylation is the process of adding a methyl group to DNA molecules. Usually, it 
happens to the cytosine of a CpG site that represents cytosine-phosphate-guanine (Figure 6). 
This transfer process is catalyzed by DNA methyltransferase enzymes (DNMTs). Therefore, if 
enzyme function is affected, the DNA methylation profile will change accordingly. This 
mechanism can happen in multiple cytosine positions, for example, 5-Methylcytosine (5-mC), 5-
hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC), 5-carboxylcytosine (5-caC), and 3-
methylcytosine (3-mC) (Figure 7). These are differentiated by the position where the methyl 
group is added to the cytosine and the added methyl group. The most commonly seen is 5-mC, 
which is also what I targeted in the Illumina DNA methylation microarray. A CpG island indicates 




Figure 6: DNA single strand structure and nucleotide structure. 
Left panel shows the bone of single-strand DNA molecules structures. The blue N represents the 
nucleobase and the difference of base which determine the nucleotide A, T, G or C. The right 
panel show the structure of four different nucleotides in DNA: top left: Cytosine (C); top right: 
Guanine (G); bottom left: Adenine (A); bottom right Thymine (T). 
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1.2.1.2 DNA methylation functions 
DNA methylation is the major epigenetic mechanism and plays an important role in 
regulating cell stage and differentiation. The most well-known function of DNA methylation is 




A B  
C D E  
 
Figure 7: Different type of DNA methylation structure.  
The green highlighted part is the adding group to cytosine. A: 5-mC; B: 5-hmC; C: 5-fC; D: 5-
caC; E: 3-mC. 
 
1.2.1.3 DNA methylation testing methods 
DNA methylation can be measured in many different ways, and how to choose the 
appropriate method depends on research interests (Figure 8). For example, MS-PCR, or 
pyrosequencing, is helpful if the study is concerned with only a few positions while sequencing-
by-synthesis, representation bisulfite sequencing (RRBS), or microarray is more suitable for 
global analysis, genome-wide methylation profile. Bisulfite conversion is a key step in measuring 
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the level of DNA methylation. Bisulfite conversion is a process whereby genomic DNA is treated 
with sodium bisulfite, leading to the deamination of unmethylated cytosines into uracil (U), while 
the methylated cytosines are protected by the methyl group and stay unchanged during the 
treatment (Figure 9).  
 
Figure 8: DNA methylation profiling technologies. 
DNA methylation profiling technologies ordered based on the 'processivity' of a technique (x axis), 
as measured by an estimate of the total number of samples analysed, and the number of CpGs 
that can be analysed per sample (y axis). Processivity was measured based on published data, 
but it also reflects the cost per assay, the time for post-processing of data and the ease of 
handling.  
Note: Figure and legend adapted from Plass, Christoph, et al. "Mutations in regulators of the 
epigenome and their connections to global chromatin patterns in cancer." Nature reviews 
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Figure 9: Bisulfite conversion process. 
Left panel shows unmethylated CpG site (red) and the right panel shows methylated CpG site 
(blue). After bisulfite conversion, the left cytosine has been changed to uracil and then replaced 
by T during amplification; the right cytosine is protected by the methyl group and keep as cytosine.  
 
1.2.2 DNA methylation microarray. 
Illumina HumanMethylation (HM) microarray is the most commonly used microarray 
platform for human genome-wide DNA methylation profiles. For each targeted CpG position, 
there are corresponding beads with specific-designed oligos attached to them. From the first 
platform (GoldenGate), HumanMethylation 27 (HM27k), to the current platform (EPIC), the 
number of probes available on the array and covered genes has exponentially increased (Table 
4). The platform available now is called Illumina HM EPIC array, and it has more than 850,000 
probes available. It is worth noting that more than 90% of probes available with the previous 
platform, HM450k, are also available in the current EPIC array. This continuity of available probes 
gives researchers the chance to merge data from different platforms and increase the sample 
size efficiently. More importantly, this platform can be used to formalin-fixed paraffin-embedded 
(FFPE) samples, which is the most common way for clinical sample storage. Depending on 
storage methods, a sample’s DNA may degrade at different levels; therefore, a restoration 
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Table 4: DNA methylation microarray evolution 
 
1.2.2.1 Microarray probe 
The Infinium probe design has been used since the HM27k platform. There are two 
different types of Infinium probes: Infinium I and II (Figure 10). For the Infinium I type, two probes 
are needed for each targeting position: one for methylated and one for unmethylated; for the 
Infinium II type probe, one probe is enough. This helps to put more probes on the limited space 
on the chip. Probes are single strand oligos (length = 50; base pair, bp) with designed DNA 
sequence which can hybridize with input DNA fragments. Probes are expected to hybridize with 
targeted DNA sequences, but mis-hybridization can happen. This leads to the so-called multi-hit 
probes, which refers to probes that hybridize with multiple DNA sequences from different 
chromosome regions (59). Besides the multi-hit problem, the SNP may also affect the probe 
hybridization (60). Those probes may cause errors during the hybridization process and further 
affect the methylation value. Therefore, it is suggested to exclude them in downstream analysis. 






GoldenGate discarded 1536 371 - 
HM27k discarded 27578 14495 Infinium I 
HM450k discarded 485764 21231 Infinium I and II 
EPIC available 867531 277365 Infinium I and II 
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Figure 10: Infinium type I and II probes.  
The top panel shows the Infinium I probe and the bottom panel shows the Infinium II probes. 
There are two probes for each targeted position in the Infinium I probe: the unmethylated 
bead/probe and the methylated bead/probe. For the unmethylated bead/probe, single strand 
oligos end with CA, which can hybridize with unmethylated CpG sites and prolong the 
hybridization with the signal (the yellow stars) while stopping the hybridization with methylated 
CpG site without a detected signal. For the methylated bead/probe, single strand oligos end with 
CG, which can hybridize with the methylated CpG sites and release the signal (the yellow stars) 
while stopping the hybridization with the unmethylated CpG sites. In contrast, Infinium type II 
only has one type of probe for both methylated and unmethylated CpG sites. The single strand 
oligos end with C, which enable hybridization with both unmethylated and unmethylated CpG 
sites. Then either A (unmethylated CpG sites) or G (methylated CpG sites) are attached to 
prolong the hybridization and release different colored signals. Then the signal intensities are 
used to calculate the methylation level. 
 
1.2.2.2 Infinium microarray protocol and controls 
Illumina Infinium array usually takes three days to run. Some steps involve internal 
controls: those probes were designed to support quality control (QC) of the assay’s stringent 
performance criteria and to demonstrate its robustness. Built-in control probes can help to identify 
samples for which data characteristics are significantly different than expected and may need to 
be excluded for further analysis. They can also provide some information about the experiment’s 
steps. There are two types of internal probes: sample-dependent and sample-independent 














unmethylated bead/probe methylated bead/probe bead/probe 
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Figure 11: Overview of Infinium microarray protocol and build-in controls 
All built-in controls are shown within the box; red boxes indicate sample-dependent controls and 
blue boxes indicate sample-independent controls. Sample-dependent control probes are used to 
evaluate sample quality and performance (red boxes) including nonpolymorphic controls, 
nonspecific binding controls, and stringency controls. Sample-dependent stringency and 
nonpolymorphic control probes are designed for human DNA and are not informative when 
working with nonhuman samples. Sample-independent control probes are used to evaluate bead 
chip and reagent performance and efficiency of hybridization and staining processes, including 
restoration, hybridization, extension, target removal, and staining controls. The restoration step 
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 Table 5: Number of internal control probes in Infinium bead chip 
Note: Table adapted from Illumina technology sheet. 
 
 For all those internal control probes, researchers use probe methylation and 
unmethylation intensity as metrics. For all probes, intensity is evaluated using both the red and 
green channels. Based on the Illumina BeadArray control reporter (BACR), specific criteria are 
applied (Table 6). 
Type controls #probes in 
HM450k 
#probes in EPIC 
sample-independent 
controls 
staining 4 6 
extension 4 4 
hybridization 3 3 
target removal 2 2 
sample-dependent 
controls 
bisulfite conversion I 12 10 
bisulfite conversion II 4 4 
specificity I 12 12 
specificity II 3 3 
negative 613 411 
nonpolymorphic 4 9 
sample-dependent norm_A 32 27 
norm_T 61 58 
norm_C 61 58 
norm_G 32 27 
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Table 6: Internal control criteria 
 
1.2.3 DNA methylation data 
For Illumina DNA microarrays, the raw data is saved as IDAT format which is human-
unreadable. After data processing, researchers can obtain both the methylated and 
unmethylated signal intensities for each probe available on the bead chip.  
1.2.3.1 Methylation metrics 
The methylation level can be measured with two values: the b-value and the M-value, 
and these can be converted into each other. The b-value has a range of 0 to 1; b-value closer to 
0 indicate less methylation, and b-value closer to 1 indicate more methylation. Because this 
microarray is used with bulk tissue, it is rare to observe exactly 0 or 1 for methylation value. In 
Control criteria note 
staining green biotin high > biotin Bkg (high/biotin Bkg) > 5 Threshold can be increased 
green channel-use lowest C 
or G and highest A or T 
intensity 
red channel-use lowest A or 
T and highest C or G 
intensity 
staining red DNP high > DNP Bkg (high/DNP Bkg) > 4 
Extension green  
lowest CG/Highest AT 
(C or G/A or T) >5 
Extension Red Lowest AT/Highest CG (C or G/A or T) >5 
Hybridization Green  




highest A or T intensity 
Target removal Green ctrl1 <= Bkg ((bkg+x)/ctrl) >1  
Target removal Green ctrl2 <= Bkg ((bkg+x)/ctrl) >1 
Bisulfite conversion I green  
C1,2,3 > U1,2,3 
(C/U)>1 Threshold can be 
increased. 
use lowest C intensity 





red highest CG 
Bisulfite conversion I green U <= bkg ((bkg+x)/U)>1 
bisulfite conversion I red  
C4,5,6>U4,5,6 
(C/U)>1 
bisulfite conversion I red U<= bkg ((bkg+x)/U)>1 
Bisulfite conversion II C red > C green (C red/C green)>1 
bisulfite conversion II C green <= bkg ((bkg+x)/C green)>1 
Specificity I green PM>MM (PM/MM)>1 use lowest PM intensity 
use highest MM intensity 
bkg=extension Green 
highest A or T intensity  
Specificity I red PM>MM (PM/MM)>1 
Specificity II S red > S green (S red/S green)>1 
specificity II S green <= bkg ((bkg+x)/S green)>1 
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contrast, b-values usually show two peaks in terms of their distribution: one around 0.1 and the 
other around 0.9 (Figure 12). The M-value is the log transformation of methylation intensities 
and its range is usually between -6 and 6 (Figure 12). A comparison (61) between these two 
metrics leads to the conclusion that it is better to use the M-value for data processing and 
calculation and to use the b-value for data visualization and demonstration. 
b − value =
	methylated	signal
methylated + unmethylated	signal + α
 








𝑀− 𝑣𝑎𝑙𝑢𝑒	 = 	𝑙𝑜𝑔2(
b− value





Figure 12: methylation b-value and M-value distribution. 
A TCGA sample with HM450k data available is used for demonstration. Left panel shows the b-
value distribution of all probes, we can clearly see two peaks which located around 0.1 and 0.9. 
These two peaks represent the unmethylated and methylated locus, respectively. Right panel 
shows the corresponding M-value distribution. We also see two peaks, which are the log-
transformed peaks of b-value. 
 
1.2.3.2 Probe annotations 
Illumina has provided comprehensive annotation for probes on the DNA methylation 
microarray. Probes are annotated by CpG island relationship, functional genomic groups, 
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Infinium type, and so on. The probes’ relationship to CpG island can be classified as CpG island, 
shore, shelf, and open sea. Shore indicates probes are 0-2k bp away from CpG islands, shelf 
indicates they are 2-4k bp away from CpG islands, and open sea indicates they are are more 
than 4k bp away from CpG islands. Probes can also be classified as TSS200 (within TSS 200 
bp), TSS1500 (within TSS 1,500 bp), 5’UTR or 3’ UTR (untranslated regions), 1st exon, body, 
and intergenic. Other than body, 3’UTR and intergenic, all categories belong to the promoter 
region. Using the probes located on HM450k platform as an example, Figure 13 has provided 
the rough distribution. 
 
Figure 13: HM450k probes percentage of annotation  
Y-axis shows the percentage of probes category over all probes and X-axis shows each category. 
A: functional genomic distribution among four different subgroups: promoter (TSS200, TSS1500, 
5’-UTR, and 1st Exon), body, 3’UTR, and intergenic. B: probe to relationship of CpG islands: CpG 
islands, shore, shelf, and open sea. C Probes distribution of chromosome location.  
 
1.2.3.3 Platform normalization 
As introduced previously, two different probe types exist for both the HM450k and the 
current HM EPIC array. Due to the different chemical technologies and different sensitivities and 
specificities, they are not directly comparable: the data distribution is different (Figure 14). Many 
different methods have been proposed to merge the data generated using Infinium type I and 
























































































































































  33 
 
(63), subset quantile within array normalization (SWAN; (64), all sample mean normalization 
(ASMN; (65) and beta-mixture quantile normalization (BMIQ; (66). These normalization methods 
are useful when trying to merge the data from the HM27k and HM450k platforms because the 
HM27k only has Infinium I probes while HM450k has both Infinium I and II probes. Some of the 
targeted CpG sites are measured with Infinium I probes in HM27k but with Infinium II probes in 
HM450k. Therefore, normalization is usually applied to the HM450k data to adjust the data 
distribution. This will be further explained in Chapter 2 in the methods section.  
 
Figure 14: Beta value distribution for Infinium type I and type II probes. 
A set of AML samples from TCGA with both HM27k and HM450k available are used for 
visualization. A: Probe cg00005847 is Infinium I type in HM27k and Infinium II type in HM450k. 
The density plot shows the different distribution of b-value. B: Probe cg00025991 is Infinium I 
type in HM27k and Infinium II type in HM450k. The density plot also shows different distribution 
of b-value. 
 
1.3 Machine learning models 
As an important subsection of artificial intelligence (AI), machine learning (ML) algorithms 
have benefited our lives in many ways, such as through facial recognition, recommendation 
engines, self-driving cars and other technological advancements. ML algorithms differ from 
traditional algorithms in that computers learn the data by themselves. ML is an interdisciplinary 
field that requires knowledge of statistics, computer science, and programming, and a 
background in the domain where it is applied. General speaking, machine learning questions can 
be categorized into two fields: supervised learning and unsupervised learning. Supervised 
learning methods train algorithms based on input and output data that is labeled by humans, and 
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unsupervised learning methods train algorithms without labeled output data and find the internal 
data structure by themselves. In short, if your data has provided labels, it is a question of 
supervised learning and vice versa. Of course, semi-supervised learning in another option when 
labeled and unlabeled data are mixed. 
By applying theory to practical problems, researchers use ML models to explore the data 
by exploring the data’s hidden patterns and structure or by building predictive models and 
applying the models to future prediction. For example, researchers can use ML algorithms to 
explore potential cancer subtypes by clustering analysis or to predict tomorrow’s weather by 
building predictive models using past weather information.  
The most commonly used unsupervised clustering algorithms are clustering methods, 
including k-means clustering, hierarchical clustering, Gaussian mixture models, and others. To 
apply clustering analysis, the most important step is to calculate the similarity or dissimilarity 
between samples. With the similarity or dissimilarity metric, samples can be grouped together 
using different algorithms. 
For supervised learning questions, there is usually a set of example data with both 
independent variables and dependent variables. In this case, researchers train models to predict 
the dependent variable using the independent variables. Many algorithms are available for 
supervised learning questions, including support vector machines (SVM), linear regression, 
logistic regression, naïve Bayes (NB), linear discriminant analysis (LDA), Gaussian discriminant 
analysis (GDA), and decision trees. According to the data type of the dependent variable, 
algorithms can also be categorized into regression or classification algorithms; if the dependent 
variable is numeric variable, regression, and if the dependent variable is categorical variable, 
classification. Regression problems sometimes can be transformed into classification problems, 
such as when using thresholds to categorize numeric value into multiple categories. But this 
transformation can lead to loss of information.  
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1.3.1 Fundamentals of ML 
To train an algorithm for a set of independent (𝑥2, 𝑥3, 𝑥b, ….) and dependent variables (𝑦), 
the main goal is to minimize the difference between predicted 𝑦e  and real observed 𝑦 
(𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = 𝑦 − 𝑦e). For example, the most commonly used solution for linear regressions is 
ordinary least square (OLS), which involves minimizing the sum of the difference between 
predicted and observed values (∑ (𝑦" − 𝑦kl)5"m2 ). Model fitting involves many interesting topics, 
such as variance bias tradeoff, variable selection, overfitting, and so on.  
1.3.1.1 variance and bias tradeoff 
Variance and bias tradeoff is also called a bias-variance dilemma or bias-variance 
problem, and it refers to how predictive models with a lower bias in parameter estimation will 
have higher variance, and vice versa. The difference between what is observed (𝑦) and what is 
predicted (𝑦e) is called error, and the error can be decomposed to variance, bias, and irreducible 
error. With fixed error, variance increase leads to lower bias, and bias increase leads to lower 
variance. Generally speaking, with increasing model complexity, the bias decreases and 
variance increases, which indicates potential overfitting risk. In contrast, with decreasing model 
complexity, the bias increases and variance decreases, which indicates underfitting risk (Figure 
15). For model building purposes, it is important to find a good balance with certain model 
complexity but without overfitting to the current available data. 
 
Figure 15: Bias and variance tradeoff plot 
Y-axis represents the model complexity and X-axis represents the value of variance or bias. We 
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complexity increases. There exists a crossing point between the variance and bias line which is 
the good balance point we are looking for. 
 
Assuming a set of data with input data points: 𝑥2, 𝑥3, .., and targeted data points 𝑦" with 
function: 𝑦 = 𝑓(𝑥) + 	𝜖, 𝜖 ∈ 𝑁(0, 𝜎3) and a function 𝑓r(𝑥)	as a good approximation of function 
𝑓(𝑥), the squared loss or squared error would be: 
𝐸𝑟𝑟(𝑥) = 𝐸t(𝑦 − 𝑓r(𝑥))3u 
Then the squared error can be decomposed as the sum of variance and bias as below: 
𝑓r(𝑥) = 𝑦e 
𝐸[(𝑦 − 𝑦e)3] = 𝐸[(𝑦 − 𝐸[𝑦e] + 𝐸[𝑦e] − 𝑦e)3]	
= 𝐸[(𝑦 − 𝐸[𝑦e])3 + (𝐸[𝑦e] − 𝑦e)3 + 2(𝑦 − 𝐸[𝑦e])(𝐸[𝑦e] − 𝑦e)]	
𝑏𝑖𝑎𝑠 = 	𝑦 − 𝐸[𝑦e]	𝑎𝑛𝑑	𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = (𝐸[𝑦e] − 𝑦e)3 = (𝑦e − 𝐸[𝑦e])3	 
This yields the following: 
𝐸[(𝑦 − 𝑦e)3] = 𝑏𝑖𝑎𝑠3 + 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 + 2 ∗ 𝐸[2(𝑦 − 𝐸[𝑦e])(𝐸[𝑦e] − 𝑦e)]	
= 𝑏𝑖𝑎𝑠3 + 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 + 2(𝑦 − 𝐸[𝑦e])(𝐸[𝐸[𝑦e] − 𝑦e])	
= 𝑏𝑖𝑎𝑠3 + 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 + 2(𝑦 − 𝐸[𝑦e])(𝐸[𝑦e] − 𝐸[𝑦e])	
= 𝑏𝑖𝑎𝑠3 + 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 
1.3.1.2 Variable selection 
In linear regression models, it is suggested to have 5-10 times the number of samples 
more than the number of parameters to get a robust model. However, in biological fields, it is 
more common to see more parameter than samples. For example, the number of genes available 
in gene expression data usually reach the thousands, and the number of samples is limited to a 
few hundred or less. With this type of high-dimension data, the data becomes very sparse, which 
hurts the robustness of model. This problem is called the curse of dimensionality. It is reasonable 
to expect smaller errors when increasing the model complexity or including more variables, but 
this may lead to overfitting and is not applicable for future data. 
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To avoid this problem, variable selection is often applied in data cleaning and 
preprocessing steps; this is an important step in building statistical models. It can help to select 
the most relevant features and exclude redundant features. It can increase productivity and 
accuracy and improve model interpretability. There are three main categories of feature selection: 
(1) Filters: Filters investigate only the intrinsic characteristics of a given data set. They are fast 
and independent of any learning methods. Two types of filters exist: feature weighting-based and 
feature searching-based filters. According to certain evaluation criterion, filtering by feature 
weighting independently measures the relevance of each feature to the target problem. Usually 
the output is weight or ranking for each feature, and features are selected based on a given 
threshold. Filtering by feature searching takes inter-feature interaction into account and 
generates a subset of features that tends to be more relevant to the target problem. 
(2) Wrappers: Wrappers differ from filters by integrating with a specific learning method. They 
search for a subset of features with optimal model performance. Usually wrappers can provide 
better results than filters, but are more computationally intensive. The variable selection models 
used in my dissertation belong to this category: variable selection within linear regression and 
random forests. 
(3) Embedded: To overcome the disadvantages of both filters and wrappers, the embedded 
method combines them and looks for a tradeoff between performance and computational costs 
by using the internal information of learning methods. 
The most commonly seen variable selection methods in linear regression are called forward 
and backward selection. Forward selection starts with a null model without any variables or 
parameters. Then it fits simple linear regression models by adding one parameter at a time. If 
the newly added parameters can statistically improve the model, then it is kept in the model, 
otherwise, it is excluded from the model. This evaluation step is repeated many times until all 
parameters have been evaluated. Backward selection is the opposite; it starts with a full model 
with all variables and parameters. Then the parameters are evaluated for their influence on the 
model. Starting with the parameter which has the least influence, parameters are excluded from 
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the model until all remaining parameters are statistically significant for the model. It is more 
common to apply forward and backward selection together; parameters are repeatedly included 
or excluded from the model to find the best combination of parameters. 
1.3.1.3 Overfitting 
As I mentioned above, with increasing model complexity, the bias decreases and 
variance increases, which indicates potential risk of overfitting. Overfitting means the model is 
overfitted to the current data set. For example, Figure 16 shows an attempt to fit a linear model 
in such a way to separate the circles from the stars. Most of the stars are located at the left top 
region, and all circles are located at the right bottom region. A simple linear regression model 
can separate them well, except in a few cases (red straight line). It is also possible to fit a more 
complicated polynomial model to make sure all circles and stars are well separated (yellow curve). 
However, this yellow curve is highly possibly overfitting to the current data and will not achieve 
good performance with future data. 
 
Figure 16: Overfitting example. 
 
Overfitting is an important issue to consider when fitting models, especially when the 
models are used for future predictions. Overfitting causes the predictive model to be useless and 
even provide wrong conclusions about future data. The most commonly used methods to avoid 
overfitting include: (1) using sample or feature bagging or bootstrapping for model fitting process; 
(2) splitting data into training, development, and test sets and fitting models with training and 
linear model
overfitting
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development sets then validated in test sets; (3) stopping early when the model is not significantly 
improved; (4) variable selection.  
1.3.1.4 Linear regression assumptions 
To apply linear regression models, four assumptions need to be satisfied (Table 7). 
Table 7: Four assumptions of linear regression model 
 
1.3.1.5 Cross-validation 
Cross-validation (CV), also called out-of-sample testing is a widely applied model 
validation technique, often used for parameter tuning. It splits all training data into n-folds, then 
uses n-1 folds to build the model and apply to the left fold. Then it changes the fold which is used 
as the test set and keeps rotating until all folds have been used as test sets (Figure 17). Cross-
validation is usually used for parameter tuning.  
 
assumption it means… be detect by… be adjust by… 
linearity Y show linearity 
with X 
residual versus X 
or residual versus 
predicted Y, or X 
versus Y 
nonlinear transformation of X or 
Y, such as logarithm, 
exponential, polynomial 
independence error independent 
over time, often 




adding lag of X or Y; adding 
variable to control the seasonal 
pattern 
homoscedasticity error independent 
of X or Y 
residual versus 
predicted Y, 
residual versus X 
nonlinear transformation of Y 
Normality error follow normal 
distribution and 
expect to be zero 
quantile-quantile 
plot (qq-plot) 
use non-linearity function; split 
data when it follows multiple 
distribution 
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Figure 17: Cross-validation example 
A whole data set has been randomly split into four folds. During the cross validation (CV) process, 
the 1st, 2nd, and 3rd folds are used to train the model and then the model is applied to the 4th fold 
in the first round. For the second round, the 1st, 2nd, and 4th folds are used to train the model and 
then model is applied to the 3rd fold. For the third round, the 1st, 3rd, and 4th folds are used to train 
the model and then model is applied to the 2nd fold. For the fourth round, the 2nd, 3rd, and 4th folds 
are used to train the model and then model is applied to the 1st fold. The order of fold usage is 
arbitrary and should not affect the results. 
 
1.3.2 Elastic Net 
In my dissertation, I used two ML methods to build predictive models: elastic net and 
random forest. A linear model fits a linear relationship among one or more independent variables 
and a dependent variable. This is the most simple and widely used type of model. The dependent 
variable can be either categorical or numerical data. Elastic net is a type of regularized linear 
regression model with L1 and L2 penalty (L1 penalty: ‖𝛽‖2 = ∑ |𝛽"|5"m2  and L2 penalty: ‖𝛽‖3 =
∑ 𝛽"35"m2 ). It combines the least absolute shrinkage and selection operator (LASSO) and ridge 
regularization to overcome the disadvantages of each method alone.  
1.3.2.1 LASSO regression 
LASSO was discovered and popularized by Robert Tibshirani in 1996. It improves the 
prediction accuracy and interpretability of regression models by variable selection. By adjusting 
the tuning parameter, l, the LASSO function can penalize the absolute size of the regression 
coefficients (Figure 18). Therefore, it can drive the coefficients of irrelevant variables to 0 and 
data set
1 fold 2 fold 3 fold 4 fold
training testing
1 fold 2 fold 3 fold 4 fold
1 fold 2 fold 3 fold4 fold
1 fold 2 fold3 fold 4 fold
1 fold2 fold 3 fold 4 fold
randomly split
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lead to variable selection. However, the LASSO method has problems with consistency: it 
generates biased parameter estimates when applied to a large set of variables. In other words, 
if researchers run LASSO multiple times with different seeds or different sample sets, it may 
select a different set of variables.  
 
Figure 18: Lasso formula 
Note: cited from the textbook “Elements of Machine Learning” 
 
1.3.2.2 Ridge regression 
Ridge regression is also called Tikhonov regularization. It is often used to deal with the 
problem of multicollinearity. Multicollinearity refers to explanatory variables showing collinearity, 
which means that as one variable increase, the other variable will also increase (positive 
relationship) or decrease (negative relationship). This can be evaluated by drawing a scatter plot 
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between two explanatory variables or by calculating correlation coefficients between variables. 
When data show multicollinearity, their least squares estimates are unbiased, but their variances 
are large so they may be inaccurate. Therefore, ridge regression adds a degree of bias to the 
regression estimates to reduce the standard errors. As shown in the formula below, the function 
adds a L2-norm in the model. This shrinks the coefficients towards zero as l increases, but they 





||𝑦 − 𝑥𝛽||33 + 𝜆||𝛽||33 
1.3.2.3 Elastic net 
Elastic net is a combination of the ridge and LASSO methods and involves adjusting the 
composition between them. In general, an elastic net model’s estimation is defined as: 
𝛽r = 𝑎𝑟𝑔𝑚𝑖𝑛(‖𝑦 − 𝑋𝛽‖3 + 𝜆3‖𝛽‖3 + 𝜆2‖𝛽‖) 
In this way, for fixed 𝜆3, elastic net first finds the ridge regression coefficients, then does a LASSO 
type shrinkage. Many software packages can apply elastic net while the most commonly used is 
an R package named glmnet: Lasso and elastic-net regularized generalized linear model (67). 
Instead of adding two parameters to each of the L1 and L2 norms, glmnet uses the following 
function to control the ratio between LASSO and ridge. When 𝛼 = 0, it applies ridge regression 
and when 𝛼 = 1, it applies LASSO regression. Then it uses the parameter 𝜆 to control the penalty 
level. The response variable can be multiple types, including quantitative families such as 
Gaussian and Poisson, categorical data type as binary or multi-classes, and survival data. 
𝜆𝛼||𝛽||2 + 𝜆(1 − 𝛼)||𝛽||33               with 0 ≤ 𝛼 ≤ 1; 𝜆 ≥ 0 
1.3.3 Random forest 
Random forest is a type of ensemble learning that constructs multiple decision trees. 
Decision tree is a decision support tool with a tree-like model of decisions and their possible 
consequences. It can be used for both regression and classification problems. It can also be 
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used to calculate the variable importance using the normalized out of bag error. Out of bag error 
technique evaluates how important the variable is by calculating the error between models with 
and without the variable.  
Random forest has the following advantages: robust to overfitting issues and robust to 
irrelevant features. As described earlier, overfitting is a critical issue that may significantly affect 
a model’s application. To avoid overfitting, researchers use the sample-level or feature-level 
bagging techniques, which involve fitting the model with randomly selected samples or features 
with a replacement. Since the irrelevant variables are rarely selected and used in trees, it does 
not affect the model performance that much. Usually, researchers can ensemble multiple shallow 
trees to avoid overfitting and reduce the biases.  
1.3.3.1 Entropy-based feature selection 
I used entropy-based algorithms in evaluation of variable importance for gene expression 
subtype prediction. Entropy is the measure of impurity, disorder, or uncertainty in a group of 
examples. It is the expectation of information from samples (𝑋).  
Η(𝑋) = 𝐸𝐼(𝑋) 
If the information of 𝑋 is defined as: 
𝐼(𝑋) = −log2	(𝑃(𝑋)) 
then the entropy is defined as: 




𝑃(𝑥")	𝑖𝑠	𝑡ℎ𝑒	𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛	𝑜𝑓	𝑠𝑎𝑚𝑝𝑙𝑒	𝑥"	𝑏𝑒𝑙𝑜𝑛𝑔𝑖𝑛𝑔	𝑡𝑜	𝑒𝑎𝑐ℎ	𝑐𝑙𝑎𝑠𝑠	𝑖	 ∈ (1, 2, …𝑛	) 
The base of the logarithm can be e, 2, or 10 and the most commonly used is 2. 𝑋 is a discrete 
random variable with potential values: {𝑥2, 𝑥3, … , 𝑥5}. In my case, I assume that 𝑋 is the classes 
I have. For example, if there are three subtypes for gene expression, then 𝑋  can be {𝑥2 =
𝐶𝐿, 𝑥3 = 𝑀𝐸𝑆, 𝑥b = 𝑃𝑁}. The maximum entropy is when 𝑝(𝑥") =
2
5
. In this case, the probability of 
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each subtype was 1/3. The minimum entropy is when the probability belonging to one subtype is 


























𝑝(𝑥") = −1 ∗ 𝑙𝑜𝑔2(1) + 0 ∗ 𝑙𝑜𝑔2(0) = 0 
The conditional entropy of two events X and Y with values of 𝑥", 𝑦$ is: 






The idea of using entropy in feature selection is that a good feature can make a better 
partition of samples. Entropy is smaller when samples partitioned into one class are more “pure” 
or “homogenous.” In contrast, entropy is higher when samples within one subclass are impure. 
In my study, I used three metrics for evaluation of variable importance that are suitable for 
categorical variables. 
1.3.3.1.1 Information gain 
Information gain (IG) measures how much “information” a feature can give about the class. 
Features that perfectly partition samples should give maximal information. Unrelated features 
should give no information. IG is often used in decision trees and random forest. 







m is the total number of samples. 
𝑚U is the total number of samples belonging to 𝑙 class. 
𝐻U is the entropy of samples belonging to 𝑙 class. 
This formula supposes there exist only two classes: 𝑙 and r. 
Using three subtypes as an example, suppose there are two features under consideration, 
feature 1 (Table 8) and feature 2 (Table 9), and three subtypes (Cl, MES, PN) targeted for 
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prediction. It is worth noting that IG can only be used for categorical independent variables. If the 
independent variables are numerical values, they are categorized into classes. 
Table 8: Confusion matrix between feature 1 annotation and observed subtypes 
Note: columns are showing the real subtype membership and the rows are showing the predicted 
subtype membership using feature 1. 
Table 9: Confusion matrix between feature 2 annotation and observed subtypes 
Note: columns are showing the real subtype membership and the rows are showing the predicted 
subtype membership using feature 1. 
 
In Table 8 and Table 9, a confusion matrix is built between subtypes predicted by feature 
(feature 1 and feature 2) and the real observed subtype. Intuitively, it is clear that feature 2 
provides better prediction or annotation than feature 1 because it has higher prediction accuracy 
(feature 1 accuracy = (10 + 15 + 20) / 85 = 0.5294 and feature 2 accuracy = (15 + 20 + 20) / 85 
= 0.6470). Then IG is calculated to compare these two features’ performance in predicting 
subtypes. 
Entropy of observed subtypes: 



















 = 1.579863 
IG of feature 1 annotation: 










 subtype: CL subtype: MES subtype: PN Subtotal 
feature 1: CL 10 10 0 20 
feature 1: MES 10 15 10 35 
feature 1: PN 5 5 20 30 
subtotal 25 20 30 85 
 subtype: CL subtype: MES subtype: PN Subtotal 
feature 2: CL 15 5 5 20 
feature 2: MES 5 20 5 35 
feature 2: PN 5 5 20 30 
subtotal 25 20 30 85 
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∗ 1.251629 = 0.2618411 
IG of feature 2 annotation: 


































































 = 1.251629 









∗ 1.251629 = 0.2931393 
Based on this calculation, it is clear that feature 2 provides more information than feature1. 
This matches the observations from the confusion table. The drawback of IG is that IG tends to 
select the features with a large number of distinct values. Applying this method, R package 
Fselector uses following formula: 
𝐼𝐺 = 𝐻(𝐶) − 𝐻(𝐶|𝐹) 
𝑤ℎ𝑒𝑟𝑒	𝐻(𝐶) =	−1 ∗ 𝑠𝑖𝑔𝑚𝑎"(𝑃(𝑐")𝑙𝑜𝑔2	𝑃(𝑐")) 
𝐻(𝐶|𝐹) = 𝑠𝑖𝑔𝑚𝑎$ 𝑃𝑓$ ∗ 𝐻𝐶	|𝑓$ 
𝐻𝐶«𝑓$ = −1 ∗ 𝑠𝑖𝑔𝑚𝑎¬(𝑃𝑐¬«𝑓$𝑙𝑜𝑔2𝑃𝑐¬«𝑓$) 
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1.3.3.1.2 Gain Ratio 
Gain ratio (GR) is the modified IG that reduces its bias on highly branching features (a 
drawback of IG). GR considers the number and size of branches when choosing a feature and 
achieves this by normalizing IG by the “intrinsic information” of a split. Intrinsic information is 












𝐷$ is the probability that sample D belongs to class j. 
High intrinsic information occurs when partitions have similar sample sizes and low 
intrinsic information occurs when few partitions have majority samples, meaning data are purer. 





With GR calculated for each feature, selection of variables with high GR is easy. The application 
of GR can be explained with the same example shown in Table 8 and Table 9. 



















































 = 1.579863 






By comparing the GR calculated for both features, it is possible to conclude that feature 
2 has a higher GR than feature 1, meaning feature 2 can better characterize the subtypes. In 
summary, compared with IG, which is biased toward multivalued features, GR tends to prefer 
unbalanced splits in which one partition is much smaller than the other. Because the unbalanced 
split will generate smaller intrinsic information value, which leads to higher gain ratio. It 
normalizes the IG by the number and size of branches. However, the problem with GR is that it 
may overcompensate and choose a subtype just because its intrinsic information is low. This can 
be fixed only by considering subtypes with greater IG than average IG. 
1.3.3.1.3 Symmetrical uncertainty 
Symmetrical uncertainty (SU) is one of the variants of mutual information (MI). MI of two 
random variables measures the mutual dependence between them. It quantifies the amount of 
information possible to obtain from one random variable by observing the other random variable. 
The MI between discrete random variables X and Y can be calculated as: 






p(x,y) is the joint probability function of X and Y. 
p(x) and p(y) have marginal probability distribution. 
The MI between continuous random variable X and Y can be calculated as: 




p(x,y) is the joint probability density function of X and Y. 
p(x) and p(y) are marginal probability density functions of X and Y respectively. 
MI has two features: nonnegative ( 𝐼(𝑋;𝑌) ≥ 0 ) and symmetric ( 𝐼(𝑋; 𝑌) = 𝑌(𝑌;𝑋) ). 
Minimum MI happens when X and Y are independent variables. In other words, information 
cannot be inferred about one variable from the other variable. This yields 𝑝(𝑥, 𝑦) = 𝑝(𝑥) ∗ 𝑝(𝑦). 
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Maximum MI happens when X and Y provide the same entropy. In other words, all information 
about one variable can be inferred from the other variable. 
SU is defined as: 








R is another measure called redundancy. 
SU can also be calculated using the harmonic mean of the two uncertainty coefficients 
𝐶°²	𝑎𝑛𝑑	𝐶²°.  An uncertainty coefficient is a measure of nominal association based on the 
information entropy. 














FSelector (R package) achieves SU as follows: 







𝑤ℎ𝑒𝑟𝑒	𝐻(𝐶) = −1 ∗ 𝑠𝑖𝑔𝑚𝑎"	𝑃(𝑐")𝑙𝑜𝑔2	𝑃(𝑐") 
𝐻(𝐶|𝐹) = 𝑠𝑖𝑔𝑚𝑎$ 	𝑃𝑓$ ∗ 𝐻	𝐶|𝑓$ 
𝐻𝐶«𝑓$ = −1 ∗ 𝑠𝑖𝑔𝑚𝑎¬(𝑃𝑐¬«𝑓$𝑙𝑜𝑔2𝑃𝑐¬«𝑓$) 
𝐻(𝐹) = −1 ∗ 𝑠𝑖𝑔𝑚𝑎"	𝑃(𝑓")𝑙𝑜𝑔2	𝑃(𝑓") 
1.4 Significance and importance 
In my study, I focused on developing DNA methylation predictive signatures and applicable 
models for gliomas’ characteristic genomic alterations. Why is this important and how can it affect 
current study in the field? It is already well-known that IDH mutation shows a strong association 
with the GCIMP signature in gliomas, but no one has ever looked into whether there are DNA 
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methylation signatures for other genomic alterations, such as somatic mutations, copy number 
variations, and gene expression subtypes. Moreover, DNA methylation is a relatively stable 
biomarker during tumor progression. For example, when comparing primary and recurrent 
gliomas, the DNA methylation profile does not show significant changes, although the gene 
expression profile can show subtypes switch. Some researchers have proposed that DNA 
methylation, as an epigenetic mechanism, can reflect the cell of origin (68). Researchers 
proposed that during the cell differentiation process, cells will acquire lineage-specific DNA 
methylation pattern which can be easily validated by comparing the methylation profile between 
different levels of differentiated cells. At the same time, new DNA methylation pattern are added 
when cells evolved to cancer cells (Figure 19) (69). Therefore, each cancer cell should harbor 
the stacked DNA methylation pattern from its lineage-specific and cancer-specific pattern. Even 
though researchers have already done comprehensive molecular profiling of tumors, information 
about tumor initiation is scarce. If DNA methylation is a stable marker of cell origin, DNA 
methylation signatures can help identify the cells with high potential to develop cancer.  
Figure 19: DNA methylation patterns in normal differentiation and cancer. 
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Normal differentiation results in the acquisition of a specific DNA methylation pattern (indicated 
in blue). Additional to the DNA methylation pattern of the cell of origin, the cancer cell acquires 
cancer specific DNA methylation changes (depicted by black stripes). 
Note: Figure adapted from Kulis, Marta, et al. "Intragenic DNA methylation in transcriptional 
regulation, normal differentiation and cancer." Biochimica et Biophysica Acta (BBA)-Gene Regulatory 
Mechanisms 1829.11 (2013): 1161-1174 with order license ID: 1001061-1. 
 
Therefore, I hypothesize that DNA methylation signature can be identified for somatic 
genomic alterations and those signatures can provide insights about genomic alterations. This 
can help develop understandings of the biology of those important genomic alterations. 
Furthermore, those genomic alterations are important features that can be used to describe and 
define tumors and their subtypes. However, there is no easy way to obtain them in clinical 
application. In clinical practice, all procedures are more complicated and must be validated and 
standardized by multiple organizations. The many rules make it hard to run tests on each patient, 
which may not seem like a big deal in research labs. For example, there hasn’t been any survival 
application in clinical trials that utilize the gene expression subtypes to categorize patients. This 
is because there is no way to obtain that information in clinical practice. With this dissertation 
done, we can easily obtain all important genomic alteration information only based on DNA 
methylation microarray, which is fast, efficient, affordable, and suitable for FFPE samples. Last 
but not least, the expansion ability of the microarray bead chip can even provide more biomarkers 
in the future.  
In summary, with my project I have developed a single-platform based DNA methylation 
biomarker prediction package, called the Unified Diagnostic (UniD) platform (Figure 20), using 
programming language R. This package accepts raw IDAT data and can run comprehensive 
data cleaning and processing procedures to generate clean, ready-to-use DNA methylation. 
More importantly, this platform can provide the binary status (mutant or wild type, codel or intact) 
of the genes IDH, ATRX, TERTp, and chr1p19q and quantitative multi-class value for gene 
expression subtypes. This package can be easily accessed through Github.  
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Figure 20: workflow of UniD package 
There are two major parts of this pipeline: data generation and diagnostic. In the data generation 
panel, it applies sample-level QC, probe-level QC, and normalization. With all filters and 
normalization applied, it can generate ready-to-use DNA methylation data for the next step. In 
the diagnostic panel, multiple genomic alterations can be predicted with DNA methylation data, 
including TCGA gene expression subtypes, MGMT methylation status, chr1p19q codel status, 
and somatic mutation status of TERTp, ATRX, and IDH. MGMT methylation status is applying 
the MGMT-STP27 model. 
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Chapter 2 
2 Binary genomic alterations prediction 
In this chapter, I will introduce the methods and results of predictive model building for 
binary genomic alterations, including mutation status of IDH, ATRX, TERTp and chr1p19q codel. 
Because the DNA methylation processing itself is complex, I will describe it in its own section. 
Next, in the methods section, I will briefly introduce DNA methylation data processing, genomic 
alterations annotation, model building, and downstream analysis. In the results section, I will 
introduce model performance, model signatures, model validation with external data sets, and 
comparison of predicted status with existing DNA methylation-based CNS classification results. 
Many different assays can be used to measure genome-wide DNA methylation profiles. 
DNA methylation microarray is one of them and is the most popular assay due to many 
advantages. For this purpose, I used the glioma samples with HM450k data available from TCGA 
project. I used the R package UniD for data processing and details are described below. 
2.1 DNA methylation data processing 
2.1.1 Data cleaning 
In the UniD package, the data generation panel has three major categories: probe-level 
QC, sample-level QC, and normalization. The probe-level and sample-level QC were applied to 
all samples and normalization was applied to HM450k data only for data merging purposes 
(merge data from HM450k with HM27k).  
2.1.1.1 Probe-level QC 
There are two types of probe-level QC: (1) sample-dependent probe exclusion, in which 
the probe is set as a missing value and it is applied sample-wisely; (2) sample-independent probe 
exclusion, in which probes are usually predefined as potential “bad probes” and will be excluded 
for all samples. It is worth noting that these two types of probe-level QC (sample-dependent or 
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sample-independent) are not the same concepts discussed as related to the internal control 
probes.  
sample-dependent probe exclusion: The missing value is assigned for a specific probe if it 
does not pass the criterion (Table 10). This is sample-dependent which means the missing value 
may be assigned to one probe in sample A but not necessarily in sample B. Three criteria are 
applied here. First of all, probes which do not pass the internal control threshold are set as 
missing. Second, probes which do not pass a background check, which means probes are not 
significantly detected when compared to background probe sets, are set as missing. Third, 
probes with less than three beads available are considered as failures and are set as missing. 
Those criteria are sample-dependently applied, which means one sample failing with a specific 
probe does not affect the same probe in other samples. Probes with high percentages of missing 
values across all samples may indicate poor quality which should be excluded from the data.  
Table 10: probe level quality control details  
  
sample-independent probe exclusion: Probes that have been predefined as “bad probes” or 
as having “potential inaccuracy” will be excluded (Table 10). For example, probes located on 
chromosome X and Y are usually excluded to avoid the sex bias in data analysis. Probes can 
probe type details of probes action for those probes 
sample 
dependent 
probes did not pass the internal control threshold assign as missing value 
probes with detection p-value >0.05 
probes with less than three beads 
sample 
independent 
probes located on chromosome X and Y recommend  
probes hybridization may affect by SNP (SNPhit) recommend  
probes may hybridize to multiple location (multihit) recommend  
probes not targeted to CpG methylation sites optional 
probes available on EPIC array but not on HM450k array optional 
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also be excluded based on research questions. For example, probes located on HM450k but not 
on EPIC will be excluded if researchers want to apply HM450k-based models to EPIC array. 
2.1.1.2 sample-level quality control 
If a sample has a high rate of missing values after the sample-dependent QC, it is highly 
possible that this sample has low quality DNA or something was wrong with the experimental 
procedures. Usually, at least 90% of probes pass QC (except sample-independent probe filters). 
If a sample has missing values for more than 10% of probes, this sample should be used carefully; 
though other probes have been successfully detected from the bead chip but their methylation 
level may be biased. 
2.1.2 normalization 
A normalization step is utilized when it is necessary to merge DNA methylation data from 
HM27k and HM450k. As described in the introduction, HM27k and HM450k use different probe 
designs and different chemical techniques: HM27k only uses Infinium I probes and HM450k uses 
both Infinium I and II probes. Infinium I and II probes generate different data distributions and 
their data are not directly comparable. Many different methods are proposed to adjust the 
difference and normalize the data to the same distribution.  
Below I present part of my master’s thesis (70) in which I discuss a data-driven method 
to compare HM450k normalization methods (material from my master thesis in italics). 
Comparison of Normalization Methods  
Probes in the HM450k array include both Infinium I and Infinium II types, while HM27k probes 
include only the Infinium I type. The β-value derived from Infinium II probes has a smaller dynamic 
range and lower sensitivity compared to data from Infinium I probes (71). Approximately 21,000 
probes overlapped between the HM450k and HM27k platforms based on probe ID. However, 
because the majority of overlapping probes from HM450k are Infinium II type probes and those 
from HM27k are mostly Infinium I probes, it is likely batch effect results when combining data 
sets. Batch adjustment is required to ensure the data are comparable between platforms. Several 
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adjustment methods have been published, such as: BMIQ (66)R package: ChAMP), SWAN (64) 
R package: lumi), and PBC (72)R package: wateRmelon). AML DNA methylation data from 
TCGA were used to evaluate adjustment methods. All 194 AML samples are available in both 
HM27k and HM450k platforms. Three steps are used to evaluate these methods, briefly 
described below (Figure 21). 
 
Figure 21: Data simulation procedures for evaluating HM450k data normalization methods. 
Section 1: Generate the gold standard. Section 2: Evaluate simulated data sets with unadjusted 
HM450k data. Section 3: Evaluate simulated data sets with adjusted HM450k data. Adjustment 
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HM27k or HM450k to do the clustering analysis with CNMF and obtain the membership for each 
platform. 2: Combine the membership results from each data set and generate the final results 
as the gold standard. 3: Simulate three data sets with HM27k and unadjusted HM450k data, 
create two subsets for each data set, and obtain the clustering results for each subset. 4: 
Compare the six results with the gold standard. 5: Obtain the concordance percentage. If the 
concordance percentage is high, the data from HM450k are used without any adjustment. If the 
concordance percentage is low, three published adjustment methods are evaluated (BMIQ, PBC, 
and SWAN). 6: For each adjustment method, four data sets are simulated. Two subsets are 
generated by MAD value. CNMF is applied for each subset. 7: Compare the membership results 
with the gold standard. 8: Generate a consistent percentage for each simulated data set. 
 
Section 1: 194 AML samples were clustered independently using the data from HM27k 
and HM450k. For each assay, probes were sorted by median absolute deviation (MAD) and the 
top 1000 and top 2000 probes were clustered using the consensus non-negative matrix 
factorization (CNMF; (73) method. These two cluster results were compared and the 
concordance between these two platforms was high. This initial classification was used as the 
gold standard. 
Section 2: Three data sets consisting of admixtures of data from the HM27k and HM450k 
data sets were simulated. Data set 1 consisted of 25% samples coming from the HM27k data 
set and 75% samples from the HM450k data set. Data set 2 consisted of 50% of samples from 
HM27k and 50% from HM450k. Data set 3 consisted of 75% samples from HM27k and 25% from 
HM450k. CNMF clustering was applied to each of the admixture data sets. The clustering results 
from each admixture data sets were compared with the gold standard. 
Section 3: For each adjustment method, the admixture process was repeated and a fourth 
data set containing only HM450k data was created. CNMF was applied to each admixture data 
set and the membership for each sample was obtained. Membership indicated the subgroup 
each sample belonged to, for example, the first AML sample may belong to subgroup 1 while the 
second AML sample belongs to subgroup 2. The membership of the classification was compared 
with the gold standard as was done for the unadjusted data sets. 
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Normalization method comparison results 
There are 194 AML samples available from TCGA and they were used for evaluation of 
adjustment methods. After deleting the probes with missing values, the HM27k data set 
contained 22,288 probes and the HM450k data set contained 393152 probes. There were 20,794 
probes overlapping between these two platforms among the 194 AML samples and the MAD 
value was calculated for each probe. The distribution of the MAD value between the HM27k and 
HM450k was highly positive-skewed (Table 11 and Figure 22). The MAD value is used to 
evaluate the variability of quantitative data. A high MAD value indicates high variability and a low 
MAD value indicates low variability. Most of the probes had a very low MAD value indicating a 
low variability among the samples for both HM27k and HM450k. Moreover, the β-value density 
distribution was different between the two data sets. 
Table 11: MAD distribution of data sets from HM27k and HM450k 
 
 
Figure 22: Distribution of two platforms 
Left: Distribution of the MAD value for HM27k and HM450k. Right: β-density distribution for 
HM27k and HM450k among the AML samples. 
 
MAD min 1st Q median mean 3rd Q max 
HM27k 0.0006097 0.0034990 0.0124800 0.0506500 0.0565700 0.5397000 
HM450k 0.0009585 0.0058600 0.0132800 0.0499000 0.0549500 0.485300 
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For both HM27k and HM450k platform, 1k and 2k probes were selected with the highest 
MAD value for the CNMF clustering analysis, respectively. Four subsets were generated. They 
were called k27_mad1k, k27_mad2k, k450_mad1k, and k450_mad2k. CNMF clustering analysis 
with data from each platform was used to generate the gold standard. Comparing the probes 
selected from k27_mad1k and k450_mad1k, 100% (1000/1000) of probes overlapped. 
Comparing the probes selected from k27_mad2k and k450_mad2k, 82.85% (1657/1000) of 
probes overlapped. This indicated that even though these two platforms have different β value 
distributions, the most variable probes have high concordance. Based on the cophenetic plot 
(Figure 23) obtained from CNMF clustering analysis, samples have the highest cophenetic 
coefficient value when k = 6. Therefore, for all comparisons in the AML data set, comparisons of 
the membership were only made when clusters were equal to 6. 
 
Figure 23: Cophenetic coefficient plot for k27_mad1k 
 
The subgroups’ attribution for each sample, designated as “membership,” was compared 
among four data sets. The number of discordant samples is provided in Table 7. The membership 
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between k27_mad1k and k27_mad2k had the lowest discordance (19/194, 9.79%). The 
membership between k27_mad2k and k450_mad1k had the highest discordance (31/194, 
15.98%). In general, the discordance was 26.2/194 (13.5%). Then the overall gold standards 
were generated by choosing the most frequent membership among these four data sets. The 
number of discordant samples between each data set and the overall gold standard is also shown 
in Table 12. 
 Table 12: Number of discordant samples among data sets used to generate gold standard 
Note: The hyphen means not applicable when the cell’s corresponding column data set and row 
data set are the same. The cells on the right of the hyphen are the number of discordant samples 
comparing the cells’ corresponding column data set and row data set. The cells on the left are 
the percentage of discordant samples comparing the cells’ corresponding column data set and 
row data set. 
 
Next, the simulating data sets were generated based on the data from HM27k and data 
from HM450k. The data from HM450k reflects four different situations: unadjusted, adjusted by 
BMIQ, adjusted by PBC, and adjusted by SWAN. The unadjusted situation included three 
simulated data sets while each adjusted situation included four simulated data sets. All simulated 
data sets were clustered by CNMF and memberships were obtained. The membership between 
each simulated data set and the overall gold standard was compared. The number of discordant 
samples is shown in Table 13 and Figure 24. As the data shows, the numbers of discordant 
samples were large when adjusting the data from HM450k with the SWAN method. This suggests 
that the SWAN method did not adjust the data for clustering analysis as well as other methods. 
By comparing the numbers of discordant samples between the SWAN method and the 
unadjusted situation, SWAN has a significantly higher number of discordant samples than in the 
unadjusted situations (Wilcox test: p-value = 0.00066). Regardless of the situations (unadjusted 
Data set k27_mad1k k27_mad2k k450_mad1k k450_mad2k 
k27_mad1k - 19 25 29 
k27_mad2k 0.097 - 31 29 
k450_mad1k 0.129 0.160 - 24 
k450_mad2k 0.149 0.149 0.124 - 
Overall Gold Standard 7 13 18 22 
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or adjusted by BMIQ or PBC methods), the number of discordant samples was compared 
between all data sets with 1k probes and all data sets with 2k probes. There was no significant 
difference between them, but the data sets with 1k probes have a lower number of discordant 
samples than data sets with 2k probes. The number of discordant samples was compared 
between unadjusted, BMIQ, and PBC, and no significant difference was observed (Wilcox test, 
unadjusted and BMIQ p-value = 0.7; Wilcox test, unadjusted and PBC p-value = 1.0; Wilcox test, 
BMIQ, and PBC p-value = 0.46.  
 
Figure 24: Percentage of concordant samples for evaluated algorithms 
 
Table 13: Membership comparison between simulated data sets and overall gold standard 
 
 
For further comparison, the membership of 27k_mad1k and 450k_mad1k was used as 
the gold standard for simulated data sets (unadjusted, BMIQ, and PBC) with 1k probes. The 

















































Unadjusted 27 34 26 55 11 12 NA NA 
BMIQ 24 32 22 46 16 18 18 12 
PBC 29 50 24 54 17 18 18 20 
SWAN 80 76 134 126 81 82 116 118 
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membership of 27k_mad2k and 450k_mad2k was used as the gold standard for simulated data 
sets (unadjusted, BMIQ, and PBC) with 2k probes. The number of discordant samples is shown 
in Table 14. There was a significant difference in the number of discordant samples between 
data sets with 1k probes and 2k probes (Wilcox test p-value = 0.0017). However, there was still 
no significant difference between the three situations unadjusted, BMIQ and PBC (Wilcox test, 
unadjusted and BMIQ p-value = 0.6092; Wilcox test, unadjusted and PBC p-value = 0.9075; 
Wilcox test, BMIQ and PBC p-value = 0.692).  
Table 14: Membership comparison between data sets and separate gold standard 
 
 Even though there was no significant difference between the unadjusted data sets and 
adjusted data sets (BMIQ and PBC), the adjusted method BMIQ still had a more stable and 
smaller number of discordant samples than the unadjusted and adjusted PBC method. Data set 
adjustment has been suggested by many papers (64, 66, 74, 75). Therefore, the BMIQ 
adjustment method was used to adjust the GBM DNA methylation data of GBM from HM450k 
before analysis. 












27k_mad1k 33 26 12 NA 
450k_mad1k 21 22 24 NA 
BMIQ 
 
27k_mad1k 27 19 15 17 
450k_mad1k 22 29 30 23 
PBC 
 
27k_mad1k 26 25 12 15 
450k_mad1k 23 33 30 13 
Unadjusted 27k_mad2k 40 57 17 NA 
 450k_mad2k 36 57 25 NA 
BMIQ 27k_mad2k 36 59 9 20 
 450k_mad2k 35 51 33 22 
PBC 27k_mad2k 52 58 15 28 
 450k_mad2k 51 61 29 29 
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Based on this data-driven analysis, it suggests that BMIQ is the best adjustment method. 
This can be applied to the HM450k data and then merged with HM27k data to increase the 
sample size.  
***end of the citation*** 
2.2 Methods 
2.2.1 DNA methylation data processing 
All gliomas with HM450k data available from TCGA were included. Samples were 
processed using the UniD package (Figure 25): remove probes not mapped to the autosomal 
chromosomes; remove probes with SNPs within 10 bases of the targeted CpG site (snp-hit) (76); 
remove probes whose sequence aligns nonspecifically (i.e. aligned to more than one location in 
the genome; multi-hit) (76). Then in a sample-wise style, probes with bead count less than or 
equal to 3 or which have not been significantly detected compared to the background (with a 
detection p-value > 0.05) were set as missing values. Probes with more than 10% missing values 
across the samples were deleted. Samples with more than 5% missing values across all probes 
were deleted due to bad quality. The remaining missing values were imputed using k-nearest 
neighbor (KNN) algorithm. 
 
Figure 25: Data processing procedures for binary genomic alterations 
Raw Data from 450K (GBM + LGG)
Exclude probes:
  located on Chr X/Y
  Affected by SNP
  Mapped to multi-sites
  Not avail on EPIC array
Set probe as missing value:
  If beadcount <=3
  if detection P>.05
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2.2.2 Somatic mutation annotation 
Genomic alterations, including mutation status of IDH, ATRX, and TERTp, and deletion 
status of chr1p19q were included. These have either mutant/codel or wild type/intact status. 
Gliomas in TCGA have been evaluated in multiple assays, including whole-exome sequencing, 
whole-genome sequencing, Affymetrix SNP6, gene expression microarray, mRNA sequencing, 
and DNA methylation microarray. Therefore, in my study, I could use either DNA or PCR 
sequencing data as a reference for mutation status of IDH, ATRX, and TERTp and use the 
chr1p19q codel status obtained from SNP6 platform as a reference label. Those data were 
directly extracted from Ceccarelli et al. (15). 
2.2.3 Model building 
After DNA methylation data processing and reference annotation extraction, I obtained 
different numbers of samples for each binary genomic alteration (Table 15). Then for each binary 
genomic alteration, all samples were randomly split into three subsets with their binary status as 
the stratification factor: a training set (60%), a development set (20%), and a test set (20%). For 
each genomic alteration, four steps (Figure 26) were used to build the model: variable selection, 
parameter tuning, model selection, and model validation. 

















IDH  637 383 127 127 DNA-seq 
TERTp 298 179 60 59 PCR-seq 
ATRX 637 383 128 126 DNA-seq 
Chr1p19q 641 385 129 127 SNP6 




Figure 26: Model building for binary genomic alterations 
The training set was used for variable selection and to build candidate models, then the candidate 
models were applied to the development set. Based on the prediction accuracy of the 
development set, the final model was selected. The final model was applied to the test set for 
model performance evaluation.  
 
Elastic net was used to select the most important probes from all available probes. Two 





+ 𝛼||𝛽||2 (0 ≤ 𝛼 ≤ 1) 
If alpha = 1, it is a lasso penalty; and if alpha = 0, it is a ridge penalty. 
For the training set, the parameter alpha (R package: glmnet (77)) was set from 0.1 to 1, 
using 0.1 as a step. For each alpha value, 200 lambda values were randomly generated. Among 
the 200 lambda values, the best lambda value was picked out according to prediction accuracy. 
For each alpha and lambda value combination, 5-fold CV was applied in the training data set. 
For each fold among the CV, a set of probes was selected to build the generalized linear model 
with a nonzero coefficient. By summarizing the selection results among 5-fold by CV, the 
percentage for each probe selected among the 5-folds was calculated. Therefore, for each alpha 
value, I obtained a set of probes and its selection percentages. Then I was able to combine the 
selected probe sets among ten alpha values and calculate their overall selection percentage. 
Probes were ranked by their selection percentage from high to low. 
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Based on the probe selection percentage ranking, different sets of top probes, with 
different numbers of probes were selected from high to low. For example, the top 100 probes, 
200 probes, 500 probes, and so on were selected. For each probe set, a generalized linear model 
was refit with the training set. Parameters were set as follows: alpha was set from 0.1 to 1, with 
0.1 as a step; for each alpha value, lambda was set from 0 to 5, with 0.05 as a step. For each 
probe set, the best alpha and lambda value combination was picked out based on their prediction 
accuracy in the development set. The final model was built using the selected parameter 
combination of alpha and lambda and the best performing probe set. The test set was unseen 
during the whole model building process and was used to evaluate the final model performance. 
The prediction accuracy was used as the main evaluation metric. Tumor purity obtained from 
ABSOLUTE (78) was compared by ANOVA among the training, development, and test sets to 
evaluate the tumor purity’s effect on model performance. 
2.2.4 Prediction results analysis 
A predictive model was built for each genomic alteration. After the final model was 
determined, all samples were rerun with the model and the methylation-based model prediction 
status was saved and further compared with the reference annotations from TCGA.  
For ATRX mutation status, samples were regrouped by the DNA-seq and methylation-
based (methyl-based) status. Misclassified samples were cases with discordant mutation status 
between DNA-seq and the methyl-based model and correctly classified samples were cases with 
concordant status between DNA-seq and the methyl-based model. To investigate whether the 
mutation types show any patterns among the misclassified samples, single nucleotide variations 
(SNVs) were obtained for misclassified samples. SNVs called with MuTect2 (79), VarScan (80), 
MuSE (81), and Somaticsniper (82) were collected from Genomic Data Commons Data Portal 
(83) and compared to the misclassified samples. 
To validate whether the ATRX mutation affects mRNA expression levels, ATRX 
expression levels among subgroups were compared using a two-sample t-test. Because the DNA 
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methylation level may affect the mRNA expression level, the methylation level of HM450k probes 
located on ATRX were compared among subgroups using ANOVA test.  
For chr1p19q codel status, samples were regrouped into four subgroups by comparing 
the chr1p19q codel status by SNP6 or by methyl-based model. For chr1p19q codel misclassified 
samples, samples’ CNV profiles were derived from HM450k probe data using the R package 
conumee (84) for visualization and validation. 
For gene expression subtype prediction, misclassified samples in the test set (n = 72) 
were regrouped by their transcriptional subtypes and predicted methylation subtypes. The 
correctly classified samples and misclassified samples were compared in terms of characteristic 
genes’ CNVs and expression level using the Wilcoxon rank sum test, such as EGFR, NF1, and 
CDKN2A. 
2.2.5 Signature analysis 
Signature probes of binary genetic alterations were aligned to the genome and analyzed 
for genomic context using a two-sample proportion test (function prop.test() in R). The following 
categories were compared for each signature:  
Chromosome enrichment. The number of probes located on each chromosome was 
summarized and normalized by the total number of probes available on the chromosome. The 
percentage for each chromosome was calculated by the normalized percent. A proportional test 
(R function, prop.test) was applied to compare the number of probes and the total number of 
probes available for each chromosome.  
CpG island relationship enrichment. Probes were categorized into following six classes 
based on their distance to CpG island: CpG island, N_shlef (2 - 4kb from island), S_shlef, 
N_shore (1 - 2kb from island), S_shore, and unknown. The first class was used if probes were 
annotated with multiple categories. A proportional test was applied to compare the number of 
probes and the total number of probes available for each category.  
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Gene structure enrichment. Probes were categorized into one of the following seven 
classes based on their relationship to functional gene structure: TSS200, TSS1500, Body, 3’-
UTR, 5’-UTR, 1st Exon, and unknown. For probes that could be mapped to multiple gene 
structure, only the first category was used. The number of probes was compared with the total 
available probes in each category using proportional test.  
Mapping genes. Genes mapped by the probes were summarized for frequency by array 
annotation. If one probe could map to multiple genes, then the first gene was counted. 
Gene ontology (GO) enrichment. Genes mapped by signature probes were analyzed with 
the DAVID tool (85) for GO enrichment analysis.  
For each binary genetic alteration, the DNA methylation probes in the predictive model 
were compared between the binary status (mutant versus wild type or intact versus codel) using 
the Wilcoxon rank sum test. The most significantly different probes were selected and used for 
unsupervised clustering. Predictive signatures of IDH, TERTp, ATRX mutation, and chr1p19q 
codel were further compared with the G-CIMP signature, previously shown to be correlated with 
IDH status (12). All statistical analyses were performed using R version 3.5.0. 
2.2.6 External data validation 
For binary genetic alterations, the phase III clinical trial NOA-04 (86) was used as an 
independent and external validation set. This trial compared the efficacy and safety of 
radiotherapy followed by chemotherapy at progression to chemotherapy followed by 
radiotherapy at progression in patients with anaplastic gliomas (n = 115). DNA methylation 
HM450k data were available for all tumor samples. Most of the tumors were characterized by 
genomic alterations and the following data served as the reference standard for comparison: 
targeted resequencing of the amplified mutational hotspot (PCR-seq) for IDH (n = 108) and 
TERTp mutation (n = 99); multiplex ligation-dependent probe amplification (MLPA) for chr1p19q 
codel (n = 99); and immunohistochemistry (IHC) for ATRX mutation (n = 96). In addition, IDH 
mutation status was also determined using unsupervised clustering analysis of HM450k data. 
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Chr1p19q codel status was also obtained by reviewing the CNV profiles derived from HM450k 
data (n = 115) (R package conumee) (84). The methyl-based binary genetic alterations were 
predicted using UniD models for all samples and compared to reference standards. The MGMT 
promoter methylation statuses obtained by MS-PCR (87) were compared with MGMT-STP27 
predictions.  
2.2.7 Comparison to existing CNS methylation-based classification 
All gliomas samples from TCGA with HM450k methylation data were run through the CNS 
methylation-based classification using the online tool. Samples were regrouped into nine subsets 
by their methyl-based predicted genetic alterations, including IDH, ATRX, and TERTp mutation 
and chr1p19q codel. The calibrated prediction CNS methylation-based class categories were 
summarized for all nine subsets. The overall survival time and status were compared among the 
major subsets. The MGMT promoter methylation status was compared using MGMT-STP27 with 
proportional tests to avoid the survival bias.  
2.3 Results 
2.3.1 Predicted results  
2.3.1.1 sample information 
I used 129 GBM and 516 LGG with HM450k data available in the data analysis. After QC 
and probe filtering, I excluded one LGG sample that did not pass the sample QC from the data 
set. After probe filtering, the final data set included 644 gliomas samples with 380,010 probes. 
Among the 644 gliomas samples, 637 of them had IDH and ATRX mutation status available, 298 
samples had TERTp mutation status annotated, and 641 of them had chr1p19q codel status 
annotated.  
2.3.1.2 Predictive models building 
IDH mutation prediction: I selected 1513 probes in the variable selection step: the top 
20, 50, 100, 200, 500, 1,000, and 1,500 probes based on importance were selected and used in 
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the candidate models (Figure 27). The IDH mutation final model used 100 probes with alpha = 
0, and lambda = 1. The final prediction accuracy was 100% in the test set. The area under the 
curve (AUC) of the receiver operator characteristic (ROC) was 1.0.  
TERTp mutation prediction: I selected 2,325 probes in the variable selection step. The 
top 50, 100, 200, 500, 1000, 1,500, and 2,000 probes were evaluated in the model selection step 
(Figure 28). The TERTp mutation final model used 1,000 probes with the same parameter 
settings in IDH prediction model. The prediction accuracy in the test was 98.3%, with an AUC of 
1.0.  
ATRX mutation prediction: I used 2,112 probes after variable selection. The top 50, 100, 
200, 500, 1,000, and 1,500 probes were evaluated in the model selection step (Figure 29). The 
final model used 500 probes with the same parameter values as IDH model. The prediction 
accuracy in the internal was 90.48% with an AUC of 0.9952.  
chr1p19q codel prediction: In variable selection, 1,279 probes showed non-zero 
importance. Again, the same modeling process was applied except that the top 20, 50, 100, 200, 
500, 1,000, and 1,279 probes were selected for model selection steps (Figure 30). The final 
model used the top 100 probes with alpha = 0 and lambda = 0.1 and reached 97.67% accuracy 
in testing set. The final model has an AUC of 0.9974.  
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Figure 27: Prediction models’ performance of IDH mutation in the training set.  
Each figure used a different number of probes and applied different alpha and lambda 
combinations. The x-axis represents the lambda value and y-axis represent the prediction 
accuracy among the 5-fold CV. Lines with different colors represent the different alpha values as 
shown in the legend. Figures A to G show the prediction accuracy using the top 20, 50, 100, 200, 
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Figure 28: Prediction model’s performance of TERTp mutation in the training set 
Each figure used a different number of probes and applied different alpha and lambda 
combinations. The x-axis represents the lambda value and y-axis represent the prediction 
accuracy among the 5-fold CV. Lines with different colors represent the different alpha values as 
shown in the legend. Figures A to G show the prediction accuracy using the top 50, 100, 200, 












0 1 2 3 4 5
Lambda
0 1 2 3 4 5
Lambda
0 1 2 3 4 5
Lambda
0 1 2 3 4 5
Lambda
0 1 2 3 4 5
Lambda
















































































































































































































































































































































































































































































































































































































































































































































































































































  73 
 
 
Figure 29: Prediction models’ performance of ATRX mutation in the training set 
Each figure used a different number of probes and applied different alpha and lambda 
combinations. The x-axis represents the lambda value and y-axis represent the prediction 
accuracy among the 5-fold CV. Lines with different colors represent the different alpha values as 
shown in the legend. Figures A to G show the prediction accuracy using the top 50, 100, 200, 
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Figure 30: Prediction models’ performance of chr1p19q codel in the training set 
Each figure used a different number of probes and applied different alpha and lambda 
combinations. The x-axis represents the lambda value and y-axis represent the prediction 
accuracy among the 5-fold CV. Lines with different colors represent the different alpha values as 
shown in the legend. Figures A to G show the prediction accuracy using the top 20, 50, 100, 200, 
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In summary, for binary genetic alterations, all predictive models achieved high prediction 
accuracy as shown in Table 16. The test set achieved a prediction accuracy of 100%, 98.3%, 
90.48%, and 99.21% for IDH, TERTp, and ATRX mutation, and chr1p19q codel status, 
respectively. 
Table 16: Binary genomic alteration predictive model performance summary 
 
Tumor purity derived by ABSOLUTE algorithm (78) was compared between training, 
development, and test set for each evaluated genomic alteration. With the exception of tumors 
with ATRX mutation (p-value = 0.043, ANOVA test), no other sample sets showed significant 










prediction accuracy (#samples) 
training set development set test set 
IDH 100 DNA-seq 637 100% (383/383) 100% (127/127) 
100% 
(127/127) 
TERTp 1000 PCR-seq 298 100% (179/179) 96.67% (58/60) 
98.3% 
(58/59) 
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Figure 31: Tumor purity comparison between training, development, and tests set for binary 
biomarker. 
From A to D, each figure shows the tumor purity compared between training, development, and 
test sets for samples used in IDH, ATRX, TERTp, and chr1p19q codel, predictive model 
development. Y-axis is the tumor purity obtained from ABSOLUTE using whole-exome 
sequencing data. X-axis is the three subsets data used in model development. Figure E shows 
the P-value of ANOVA-test in comparing the tumor purity between the three subsets.  
 
2.3.2 Predictive signature analysis 
By comparing the number of probes enriched for chromosomes after normalization, I 
found that probes in the IDH mutation prediction model were enriched in chromosomes 22 
(13.08%) and 21 (8.8%), while probes in the ATRX mutation prediction model were enriched in 
chromosomes 9 (7.2%) and 14 (7.2%). Interestingly, probes in the TERTp mutation, chr1p19q 
codel, and gene expression subtype prediction models were enriched in chromosome 18 (TERTp: 
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1 36923 8 0.022% 3.343% 
0.1314 
2 27711 13 0.047% 7.239% 
3 20279 7 0.035% 5.326% 
4 16241 2 0.012% 1.900% 
5 19398 3 0.015% 2.386% 
6 28392 5 0.018% 2.717% 
7 23237 3 0.013% 1.992% 
8 16401 2 0.012% 1.882% 
9 7783 4 0.051% 7.930% 
10 18784 6 0.032% 4.929% 
11 23487 8 0.034% 5.256% 
12 20018 5 0.025% 3.854% 
13 9794 2 0.020% 3.151% 
14 12234 2 0.016% 2.523% 
15 12402 4 0.032% 4.977% 
16 17917 3 0.017% 2.584% 
17 23237 3 0.013% 1.992% 
18 4939 1 0.020% 3.124% 
19 21429 8 0.037% 5.761% 
20 8823 3 0.034% 5.247% 
21 3507 2 0.057% 8.800% 
22 7074 6 0.085% 13.088% 
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1 36923 88 0.238% 4.023% 
0.0000352 
 
2 27711 81 0.292% 4.934% 
3 20279 60 0.296% 4.994% 
4 16241 45 0.277% 4.677% 
5 19398 54 0.278% 4.699% 
6 28392 74 0.261% 4.399% 
7 23237 85 0.366% 6.175% 
8 16401 44 0.268% 4.528% 
9 7783 18 0.231% 3.904% 
10 18784 32 0.170% 2.876% 
11 23487 51 0.217% 3.665% 
12 20018 41 0.205% 3.457% 
13 9794 25 0.255% 4.309% 
14 12234 28 0.229% 3.863% 
15 12402 33 0.266% 4.491% 
16 17917 38 0.212% 3.580% 
17 23237 65 0.280% 4.722% 
18 4939 24 0.486% 8.202% 
19 21429 49 0.229% 3.860% 
20 8823 44 0.499% 8.418% 
21 3507 5 0.143% 2.407% 
22 7074 16 0.226% 3.818% 
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1 36923 56 0.152% 5.347% 
0.01635 
 
2 27711 37 0.134% 4.708% 
3 20279 18 0.089% 3.129% 
4 16241 18 0.111% 3.908% 
5 19398 28 0.144% 5.089% 
6 28392 30 0.106% 3.725% 
7 23237 32 0.138% 4.855% 
8 16401 27 0.165% 5.804% 
9 7783 16 0.206% 7.248% 
10 18784 14 0.075% 2.628% 
11 23487 30 0.128% 4.503% 
12 20018 28 0.140% 4.932% 
13 9794 3 0.031% 1.080% 
14 12234 25 0.204% 7.205% 
15 12402 17 0.137% 4.833% 
16 17917 33 0.184% 6.494% 
17 23237 26 0.112% 3.945% 
18 4939 3 0.061% 2.142% 
19 21429 33 0.154% 5.430% 
20 8823 15 0.170% 5.994% 
21 3507 3 0.086% 3.016% 
22 7074 8 0.113% 3.987% 
  80 
 
Table 20: Chromosome enrichment analysis for chr1p19q codel prediction signatures 
 
Summarizing the dispersion of probes by chromosome, I found most of the probes were 
enriched on CpG islands. Among the four predictive models, the IDH predictive signature showed 
the highest percentage of CpG islands (76%) (Table 21). For the other three predictive signatures, 


























1 36923 3 0.008% 1.305% 
0.003735 
 
2 27711 6 0.022% 3.477% 
3 20279 6 0.030% 4.751% 
4 16241 6 0.037% 5.932% 
5 19398 6 0.031% 4.966% 
6 28392 11 0.039% 6.221% 
7 23237 13 0.056% 8.983% 
8 16401 7 0.043% 6.853% 
9 7783 1 0.013% 2.063% 
10 18784 8 0.043% 6.838% 
11 23487 4 0.017% 2.735% 
12 20018 4 0.020% 3.208% 
13 9794 1 0.010% 1.639% 
14 12234 3 0.025% 3.937% 
15 12402 1 0.008% 1.295% 
16 17917 1 0.006% 0.896% 
17 23237 4 0.017% 2.764% 
18 4939 5 0.101% 16.255% 
19 21429 3 0.014% 2.248% 
20 8823 5 0.057% 9.099% 
21 3507 0 0.000% 0.000% 
22 7074 2 0.028% 4.540% 
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Table 21: CpG island relationship enrichment for IDH mutation prediction signatures 
 
Table 22: CpG island relationship enrichment for TERTp mutation prediction signatures 
 






















Island 120312 89 0.074% 75.9958% 
<2.2e-16 
N_Shelf 18946 0 0.000% 0.0000% 
N_Shore 50338 5 0.010% 10.2043% 
S_Shelf 16765 0 0.000% 0.0000% 
S_Shore 39412 5 0.013% 13.0332% 
not 




















Island 120312 536 0.446% 33.104% 
<2.2e-16 
N_Shelf 18946 30 0.158% 11.766% 
N_Shore 50338 100 0.199% 14.762% 
S_Shelf 16765 31 0.185% 13.740% 
S_Shore 39412 74 0.188% 13.952% 
not 




















Island 120312 261 0.217% 31.313% 
<2.2e-16 
N_Shelf 18946 18 0.095% 13.713% 
N_Shore 50338 71 0.141% 20.359% 
S_Shelf 16765 6 0.036% 5.166% 
S_Shore 39412 54 0.137% 19.777% 
not 
categorized 134237 90 0.067% 9.677% 
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Table 24: CpG island relationship enrichment for chr1p19q prediction signatures 
 
Among the 100 probes with IDH predictive signatures, 45% of the probes (45/100) were 
located in the promoter region (including TSS200, TS1500, and 1st Exon) (Table 25). In total 65 
genes were mapped by those 100 probes. Among all genes, CASP8 and FADD like apoptosis 
regulator (CFLAR) genes had four probes mapped and nuclear receptor subfamily 4, group A, 
member 1 (NR4A1) had three probes mapped. Applying those 65 genes to the DAVID (85, 88) 
(version 6.7) for functional annotation, the top GOs enriched pathways were regulation of 
apoptosis (p-value = 0.0052), regulation of programmed cell death (p-value = 0.0056), and 
regulation of cell death (p-value = 0.0057) (Table 26). Genes related to those GOs were CFLAR, 
tumor necrosis factor receptor superfamily member 6 (FAS); potassium voltage-gated channel 
interacting protein 3 (KCNIP3); death effector domain containing 2 (DEDD2); lectin, galactoside-
binding, soluble, 1 (LGALS1); NR4A1; proline dehydrogenase 1 (PRODH); retinoic acid receptor, 
gamma (RARG); and erb-b2 receptor tyrosine kinase 2 (ERBB2). Those GOs were not significant 

























Island 120312 53 0.044% 32.777% 
0.0001692 
N_Shelf 18946 1 0.005% 3.927% 
N_Shore 50338 14 0.028% 20.693% 
S_Shelf 16765 4 0.024% 17.752% 
S_Shore 39412 7 0.018% 13.215% 
not 
categorized 134237 21 0.016% 11.640% 
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Table 25: Gene structure enrichment for IDH mutation prediction signatures 
 


















TSS200 41774 20 0.048% 22.055% 
0.00004473 
TSS1500 55088 13 0.024% 10.871% 
Body 126827 23 0.018% 8.354% 
3'UTR 13641 0 0.000% 0.000% 
5'UTR 33719 14 0.042% 19.127% 
1st Exon 18147 12 0.066% 30.462% 
not 
categorized 90814 18 0.020% 9.131% 
Category Term Count P-Value Benjamini-adjust p-value 
 GOTERM_BP_FAT  sensory organ development 6 0.001 0.51 
GOTERM_BP_FAT regulation of apoptosis 9 0.0052 0.84 
GOTERM_BP_FAT regulation of programmed cell death 9 0.0056 0.72 
GOTERM_BP_FAT regulation of cell death 9 0.0057 0.63 
GOTERM_BP_FAT muscle cell differentiation 4 0.008 0.67 
GOTERM_BP_FAT positive regulation of apoptosis 6 0.015 0.82 
GOTERM_BP_FAT positive regulation of programmed cell death 6 0.015 0.78 
GOTERM_BP_FAT positive regulation of cell death 6 0.016 0.74 
GOTERM_BP_FAT negative regulation of cell activation 3 0.018 0.76 
GOTERM_BP_FAT regulation of lymphocyte differentiation 3 0.019 0.74 
GOTERM_BP_FAT regulation of cell activation 4 0.022 0.74 
GOTERM_BP_FAT induction of apoptosis 5 0.023 0.74 
GOTERM_BP_FAT induction of programmed cell death 5 0.023 0.71 
GOTERM_BP_FAT cartilage development 3 0.026 0.73 
GOTERM_BP_FAT regulation of cell size 4 0.033 0.78 
GOTERM_BP_FAT regulation of T cell differentiation in the thymus 2 0.037 0.8 
GOTERM_BP_FAT embryonic eye morphogenesis 2 0.04 0.81 
GOTERM_BP_FAT homeostatic process 7 0.041 0.8 
GOTERM_BP_FAT regulation of cell proliferation 7 0.049 0.84 
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For TERTp predictive signatures, most of the probes were located at the body (29.1%) 
(Table 27). Probes were mapped to 612 genes in total, and the most frequently mapped gene 
was isthmin 1 (ISM1) with ten probes. The second most frequently mapped gene was atlastin 
GTPase 3 (ATL3) with seven probes. For gene functional annotation, the most significant GOs 
were all related to the regulation of transcription (Table 28).  



















TSS200 41774 162 0.388% 16.700% 
< 2.2e-16 
TSS1500 55088 130 0.236% 10.162% 
Body 126827 291 0.229% 9.881% 
3'UTR 13641 96 0.704% 30.306% 
5'UTR 33719 34 0.101% 4.342% 
1st Exon 18147 79 0.435% 18.747% 
not 
categorized 90814 208 0.229% 9.863% 
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Table 28: GO enrichment analysis results for TERTp mutation prediction signatures 
 
For ATRX predictive signature, most of the probes were located at the body (13.9%) 
(Table 29). In total, probes were mapped to 333 genes. Gene F-box protein 6 (FBXO6) had five 
probes mapped, and cathepsin F (CTSF) gene was mapped by four probes. Using the DAVID 
gene functional annotation, genes were significantly enriched in development related GOs, 
including embryonic development and neuron development (Table 30). I further compared the 
70 probes overlapping the ATRX predictive signature and TERTp predictive signature; 52 genes 
Category Term Count P-Value Benjamini-adjust p-value 
GOTERM_BP_FAT regulation of transcription 131 9.100E-08 0.00022 
GOTERM_BP_FAT regulation of transcription, DNA-dependent 97 2.300E-07 0.00028 
GOTERM_BP_FAT regulation of RNA metabolic process 97 6.400E-07 0.00052 
GOTERM_BP_FAT regulation of transcription from RNA polymerase II promoter 49 2.400E-06 0.0014 
GOTERM_BP_FAT negative regulation of transcription, DNA-dependent 30 5.700E-06 0.0027 
GOTERM_BP_FAT negative regulation of transcription from RNA polymerase II promoter 25 6.600E-06 0.0027 
GOTERM_BP_FAT negative regulation of RNA metabolic process 30 7.800E-06 0.0027 
GOTERM_BP_FAT negative regulation of macromolecule biosynthetic process 39 9.200E-06 0.0028 
GOTERM_BP_FAT negative regulation of biosynthetic process 40 1.100E-05 0.003 
GOTERM_BP_FAT negative regulation of cellular biosynthetic process 39 1.600E-05 0.0039 
GOTERM_BP_FAT negative regulation of transcription 34 1.800E-05 0.004 
GOTERM_BP_FAT 
negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolic process 
35 6.700E-05 0.014 
GOTERM_BP_FAT negative regulation of nitrogen compound metabolic process 35 8.800E-05 0.016 
GOTERM_BP_FAT negative regulation of gene expression 34 1.100E-04 0.019 
GOTERM_BP_FAT negative regulation of macromolecule metabolic process 44 1.400E-04 0.022 
GOTERM_BP_FAT transcription 98 1.700E-04 0.025 
GOTERM_BP_FAT pattern specification process 22 1.800E-04 0.025 
GOTERM_BP_FAT positive regulation of gene expression 36 3.500E-04 0.046 
GOTERM_BP_FAT positive regulation of transcription 35 4.200E-04 0.053 
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were mapped. Most of the genes were enriched during transcription regulation. The most 
frequently mapped gene was FBXO6 and phosphodiesterase 7B (PDE7B). The top GOs 
enriched for those overlapping genes was cell - cell signaling (Table 31).  
 Table 29: Gene structure enrichment for ATRX mutation prediction signatures 
 



















TSS200 41774 71 0.170% 14.037% 
< 2.2e-16 
TSS1500 55088 67 0.122% 10.044% 
Body 126827 139 0.110% 9.051% 
3'UTR 13641 55 0.403% 33.299% 
5'UTR 33719 10 0.030% 2.449% 
1st Exon 18147 46 0.253% 20.934% 
not 
categorized 90814 112 0.123% 10.185% 
Category Term Count P-Value Benjamini-adjust p-value 
GOTERM_BP_FAT chordate embryonic development 18 6.100E-05 0.097 
GOTERM_BP_FAT embryonic development ending in birth or egg hatching 18 6.800E-05 0.055 
GOTERM_BP_FAT neuron fate commitment 7 7.600E-05 0.042 
GOTERM_BP_FAT endocrine system development 8 1.800E-04 0.072 
GOTERM_BP_FAT regionalization 12 6.200E-04 0.19 
GOTERM_BP_FAT embryonic skeletal system development 7 2.100E-03 0.44 
GOTERM_BP_FAT pattern specification process 13 2.300E-03 0.43 
GOTERM_BP_FAT gland development 9 2.300E-03 0.39 
GOTERM_BP_FAT regulation of cell development 11 2.900E-03 0.42 
GOTERM_BP_FAT regulation of phosphorylation 18 2.900E-03 0.39 
GOTERM_BP_FAT skeletal system development 14 3.600E-03 0.42 
GOTERM_BP_FAT muscle organ development 11 3.600E-03 0.4 
GOTERM_BP_FAT neuron differentiation 17 3.800E-03 0.39 
GOTERM_BP_FAT muscle organ morphogenesis 3 4.200E-03 0.4 
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 Table 31: overlapped probes between ATRX and TERTp predictive signature mapped genes 
enrichment GO 
 
For chr1p19q codel prediction signature, 44% of probes mapped to the promoter region, 
including TSS200, TSS1500, and 1st Exon (Table 32). Four probes mapped to gene ATL3 and 
fibroblast growth factor receptor 2 (FGFR2). The top two GOs were regulation of cellular protein 
metabolic process (p-value = 0.001) and bone morphogenetic proteins (BMP) signaling pathway 
(p-value = 0.0098). However, no GOs were significant after Benjamin p-value adjustment (Table 
33). 
 
Category Term Count P-Value Benjamini-adjust p-value 
GOTERM_BP_FAT cell-cell signaling 11 8.400E-04 0.7 
GOTERM_BP_FAT regulation of cell communication 15 2.000E-03 0.77 
GOTERM_BP_FAT positive regulation of cellular component biogenesis 6 2.100E-03 0.64 
GOTERM_BP_FAT regulation of signaling 15 2.400E-03 0.57 
GOTERM_BP_FAT regulation of transcription from RNA polymerase II promoter 11 3.600E-03 0.64 
GOTERM_BP_FAT cellular component assembly 13 5.400E-03 0.72 
GOTERM_BP_FAT regulation of cellular component biogenesis 7 6.200E-03 0.72 
GOTERM_BP_FAT positive regulation of developmental process 8 6.700E-03 0.7 
GOTERM_BP_FAT regulation of multicellular organismal development 10 7.700E-03 0.71 
GOTERM_BP_FAT positive regulation of multicellular organismal process 9 8.400E-03 0.7 
GOTERM_BP_FAT transcription from RNA polymerase II promoter 10 1.100E-02 0.76 
GOTERM_BP_FAT cellular component biogenesis 13 1.300E-02 0.78 
GOTERM_BP_FAT positive regulation of macromolecule biosynthetic process 9 1.600E-02 0.83 
GOTERM_BP_FAT protein secretion 5 1.600E-02 0.81 
GOTERM_BP_FAT regulation of cellular component organization 11 1.800E-02 0.83 
GOTERM_BP_FAT positive regulation of transcription from RNA polymerase II promoter 7 2.000E-02 0.84 
GOTERM_BP_FAT regulation of signal transduction 12 2.000E-02 0.82 
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TSS200 41774 16 0.038% 17.652% 
0.005519 
TSS1500 55088 19 0.034% 15.896% 
Body 126827 24 0.019% 8.722% 
3'UTR 13641 2 0.015% 6.757% 
5'UTR 33719 15 0.044% 20.503% 
1st Exon 18147 9 0.050% 22.858% 
not 
categorized 90814 15 0.017% 7.613% 
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Table 33: GO enrichment analysis results for chr1p19q codel mutation prediction signatures 
 
For each binary genetic alteration, samples were clustered into two subgroups with the 
highest ranked significantly different probes and showed high consistency with the known 
genomic alteration (Figure 32A). By comparing the signature probes of IDH, TERTp, ATRX, and 
chr1p19q codel with the G-CIMP signature, I found that no probes overlapped among these five 
probe signatures (Figure 32B). The lack of overlap between ATRX and TERTp mutation 
Category Term Count P-Value Benjamini-adjust p-value 
GOTERM_BP_FAT regulation of cellular protein metabolic process 8 1.000E-03 0.44 
GOTERM_BP_FAT BMP signaling pathway 3 9.800E-03 0.94 
GOTERM_BP_FAT regulation of protein modification process 5 1.800E-02 0.96 
GOTERM_BP_FAT regulation of protein amino acid phosphorylation 4 2.100E-02 0.95 
GOTERM_BP_FAT tissue morphogenesis 4 2.300E-02 0.93 
GOTERM_BP_FAT enzyme linked receptor protein signaling pathway 5 2.800E-02 0.93 
GOTERM_BP_FAT 
negative regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid 
metabolic process 
6 2.900E-02 0.91 
GOTERM_BP_FAT negative regulation of nitrogen compound metabolic process 6 3.100E-02 0.89 
GOTERM_BP_FAT negative regulation of macromolecule biosynthetic process 6 3.700E-02 0.91 
GOTERM_BP_FAT negative regulation of cellular biosynthetic process 6 4.100E-02 0.9 
GOTERM_BP_FAT negative regulation of biosynthetic process 6 4.400E-02 0.9 
GOTERM_BP_FAT positive regulation of cellular protein metabolic process 4 4.500E-02 0.88 
GOTERM_BP_FAT morphogenesis of an epithelium 3 4.600E-02 0.87 
GOTERM_BP_FAT 
transmembrane receptor protein 
serine/threonine kinase signaling 
pathway 
3 4.800E-02 0.86 
GOTERM_BP_FAT positive regulation of protein metabolic process 4 4.900E-02 0.85 
GOTERM_BP_FAT ossification 3 5.800E-02 0.88 
GOTERM_BP_FAT bone development 3 6.500E-02 0.89 
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signatures was consistent with the mutually exclusive nature of ATRX and TERTp in telomere 
maintenance(89). 
 
Figure 32: Methyl-based predictive signature analysis for binary genomic alterations 
A Heatmaps of DNA methylation level (b value): samples are in columns and DNA methylation 
probes are in rows. The two top sidebars show the sample source and genetic alteration status. 
From left to right, each image shows the most significant probes in signatures of IDH (number of 
probes = 100), TERTp (number of probes = 200), ATRX (number of probes = 90), and chr1p19q 
codel (number of probes = 70). B In this Venn diagram, the predictive model probes of each 
binary genetic alteration (number of probes: IDH = 100, TERTp = 1,000, ATRX = 500, chr1p19q 
codel = 100) and the GCIMP probes (number of probes = 818) identified in published paper (12) 
were compared with each other. Different colors represent different probe sets. The overlapping 
blocks between any probes sets indicate the overlapping probes. The number within the diagram 
indicates the number of probes within a specific block.  
 
2.3.3 Prediction results analysis 
For ATRX mutation status, 42 samples were misclassified by the methylation-based 
model. To investigate the mutation types (such as missense, nonsense, frameshift, and so on) 
of those samples, the SNV information was collected and compared among misclassified 
samples. 
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Five sets (sets 1 to 5) were formed based on the DNA-seq based ATRX status (mutant 
or wild type), methyl-based ATRX status (mutant or wild type), and SNV information (with 
mutation detected or not detected) (Figure 33A). Twenty-five samples were classified as wild 
type by DNA-seq but mutant by methyl-based model (Table 34). Among these 25 samples, 17 
samples (set 2) showed at least 1 mutation call from the 4 SNV algorithm results and 8 samples 
(set 3) had no mutation calls according to the SNVs (Figure 33B). For set 4, samples with TERTp 
mutation status, 3 of the 8 were TERTp mutant and wild type for ATRX. All samples misclassified 
as ATRX mutant by methyl-based model harbored IDH mutation while all samples misclassified 
as wild type by methyl-based model were IDH wild type (Figure 33B). A mutation type shift 
occurred between set 2 (ATRX DNA-seq wild type, methyl-based mutant, and with mutation calls 
by reviewing SNV information) and set 4 (ATRX DNA-seq mutant, methyl-based wild type): the 
enriched mutations shifted from frameshift indels and in-frame indels to intron, missense and 
nonsense which may not lead to loss of function. No significant differences in ATRX gene 
expression were observed between sets for which methylation results agreed, even when the 
sequencing result was discordant between those sets. Conversely, when the methylation results 
were discordant, even when the sequencing results were in an agreement, a significant 
difference in expression was observed (Figure 33CD). The DNA methylation level of probes 
located on ATRX did not show significant differences among the three subsets with the exception 
of a single probe (Figure 34).  
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Figure 33: Investigation of misclassified samples for ATRX prediction 
A All samples (n = 637) used to build the methyl-based predictive model for ATRX are classified 
into five subgroups based on DNA-seq and methyl-based ATRX mutation status and on whether 
they had mutation calls by reviewing the SNV information. B The misclassified 42 samples are 
shown with their tumor type, mutation status, mutation calling algorithms, and detailed mutation 
type. C Boxplots show the ATRX gene expression level for each set. By applying Wilcoxon rank 
sum test, set 2 and set 3 samples show significantly lower ATRX expression level than set 1 (set 
2 versus set 1: the estimated difference was 1.134 and 95%CI was 0.67 to 1.47, p-value = 
3.97´10-7, set 3 versus set 1: the estimated difference was 1.33 and 95%CI was 0.83-1.81, p-
value = 5.54´10-5) and set4 showed significantly higher ATRX expression level compared to set 
5 (the estimated difference was 0.87 and 95% CI 0.47 to 1.27, p-value = 1´10-4). D T-test was 
used to compare ATRX gene expression level between every two subsets. The p-value is 












































































































*p-value: wilcoxon rank sum test
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Table 34: ATRX prediction results analysis for misclassified samples 
sample 
ATRX status Find in algorithms (Yes/No) #detected 
times 
IDH 
status DNA-seq Methyl Muse somaticsniper Varscan Mutect 
TCGA-WY-A85C-01A WT mutant No No No No 0 Mutant 
TCGA-WY-A859-01A WT mutant No No No No 0 Mutant 
TCGA-WH-A86K-01A WT mutant No No No No 0 Mutant 
TCGA-S9-A7R4-01A WT mutant No No No No 0 Mutant 
TCGA-P5-A5F4-01A WT mutant No No No No 0 Mutant 
TCGA-DH-5143-01A WT mutant No No No No 0 Mutant 
TCGA-DB-5277-01A WT mutant No No No No 0 Mutant 
TCGA-CS-5393-01A WT mutant No No No No 0 Mutant 
TCGA-26-1442-01A-01D WT mutant No Yes No No 1 Mutant 
TCGA-CS-6665-01A-11D WT mutant No No No Yes 1 Mutant 
TCGA-HT-7606-01A-11D WT mutant No No No Yes 1 Mutant 
TCGA-HT-8018-01A-11D WT mutant No No No Yes 1 Mutant 
TCGA-HW-A5KM-01A WT mutant No No No Yes 1 Mutant 
TCGA-S9-A7R3-01A-11D WT mutant No No No Yes 1 Mutant 
TCGA-S9-A89Z-01A-11D WT mutant No No No Yes 1 Mutant 
TCGA-TQ-A7RF-01A WT mutant No No No Yes 1 Mutant 
TCGA-TQ-A7RW-01A WT mutant No No No Yes 1 Mutant 
TCGA-TQ-A8XE-01A WT mutant No No No Yes 1 Mutant 
TCGA-06-6389-01A-11D WT mutant No No Yes Yes 2 Mutant 
TCGA-DB-A4XB-01A WT mutant No Yes No Yes 2 Mutant 
TCGA-S9-A7J0-01A-11D WT mutant No No Yes Yes 2 Mutant 
TCGA-DU-8167-01A-11D WT mutant Yes No Yes Yes 3 Mutant 
TCGA-DB-A4X9-01A-11D WT mutant Yes Yes Yes Yes 4 Mutant 
TCGA-HT-7601-01A-11D WT mutant Yes Yes Yes Yes 4 Mutant 
TCGA-HW-8321-01A WT mutant Yes Yes Yes Yes 4 Mutant 
TCGA-06-A5U0-01A-11D mutant WT No No Yes Yes 2 WT 
TCGA-DU-7298-01A-11D mutant WT No No Yes Yes 2 Mutant 
TCGA-HT-7469-01A-11D mutant WT No No Yes Yes 2 WT 
TCGA-HT-7857-01A-11D mutant WT No No Yes Yes 2 WT 
TCGA-DU-5852-01A-11D mutant WT No Yes Yes Yes 3 WT 
TCGA-S9-A89V-01A-11D mutant WT Yes No Yes Yes 3 WT 
TCGA-06-5858-01A-01D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-06-6388-01A-12D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-06-6391-01A-11D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-4W-AA9T-01A-11D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-74-6575-01A-11D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-DH-5144-01A-01D mutant WT Yes Yes Yes Yes 4 Mutant 
TCGA-DU-6392-01A-11D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-FG-5963-01A-11D mutant WT Yes Yes Yes Yes 4 WT 
TCGA-FG-7638-01B-11D mutant WT Yes Yes Yes Yes 4 Mutant 
TCGA-FG-A713-01A-11D mutant WT Yes Yes Yes Yes 4 Mutant 
TCGA-HT-7880-01A-11D mutant WT Yes Yes Yes Yes 4 Mutant 
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Figure 34: Investigation of HM450k probes located on ATRX. 
A The heatmap shows the methylation beta value of HM450k probes located at the ATRX gene 
region (TSS200, TSS1500, 1st Exon, and body) for samples in set 2, set 3, and set 4. Each 
column represents one sample while each row represents one probe. The column-sidebar 
indicates the subset samples belong to while the row-sidebar indicates the annotations for probes. 
B The boxplot shows the comparison of DNA methylation level of probe cg00594844 among the 
set 2, set 3, and set 4. The y-axis shows the DNA methylation level (M-value) and the x-axis 
shows the three sets. This is the only probe that showed different methylation levels (p-value = 
0.0213, ANOVA test) among the three subsets. 
 
For the chr1p19q codel prediction model, samples were classified into four different sets (set 
1 to 5) by their methyl-based IDH status, SNP6-based chr1p19q status, and methyl-based 
chr1p19q status (Figure 35A). I observed clear concordance between the methyl-based 
chr1p19q codel status and other known somatic mutations for different sets. Five samples were 
misclassified when comparing methyl-based status to SNP6-based status (Figure 35B). The 
CNV profile of chr1 and chr19 were derived from the HM450k methylation data using R package 
conumee(84) (Figure 35C). Four over five samples were misclassified as codel and one sample 
was misclassified as non-codel by methylation model. The deletion in the TCGA-CS-5394 and 
TCGA-FG-7637 which match with methyl-based model prediction is clear to see. The CNV profile 
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Figure 35: Investigation of misclassified samples for chr1p19q codel prediction model 
A Genetic characterization of subsets (set 1 to set 6) according to chr1p19q codel status 
determined by SNP6 and methyl-based prediction. Set 1 samples (IDH wild type and chr1p19q 
intact from both SNP6-based and methyl-based) show frequent TERTp mutations and majority 
wild type status of CIC, FUBP1, ATRX, and TP53. Set 2 samples (IDH mutation and chr1p19q 
intact by both SNP6-based and methyl-based) show frequent mutation for CIC, FUBP1, ATRX, 
and TP53, and lacked TERTp mutation. Set 5 (IDH mutation and chr1p19q codel from both 
SNP6-based and methyl-based status) show frequent TERTp, CIC, and FUBP1 mutations but 
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SNP6 CNV intact) show consistency mutation profile with set2. B Genetic characterization of the 
five misclassified samples by comparing methyl-based chr1p19q status to SNP6-based 
chr1p19q status. C CNV profile of chr1 and chr19 of the five misclassified samples were derived 
from HM450k data using R package conumee. 
 
2.3.4 Model validation 
The prediction accuracy for each biomarker in the NOA-04 cohort was: 89.9% (98/109) for 
IDH mutation by PCR-seq and 99.10% (114/115) for IDH mutation by unsupervised clustering 
analysis, 82.8% (82/99) for TERTp mutation by PCR-seq, 92.7% (89/96) for ATRX mutation by 
IHC, and 88.89% (88/99) for chr1p19q status by MLPA and 95.65% (110/115) for chr1p19q 
status by HM450k-based CNV profiles (Table 35). In terms of IDH mutation status, 11 samples 
were misclassified by methyl-based prediction: nine of them were predicted as wild type by PCR-
seq and mutant by the methyl-based model. MGMT methylation status comparisons are shown 
in Table 36.  
Table 35: Binary genomic predictive model validation using NOA-04 data set 
 
 
Table 36: MGMT promoter methylation status comparison between MS-PCR and MGMT-




Genomic alteration #samples reference label prediction Accuracy 
IDH 
108 PCR-seq 89.90% 
115 HM450k clustering 99.10% 
TERTp 99 PCR-seq 82.80% 
ATRX 96 IHC 92.70% 
chr1p19q 
99 MLPA 89.99% 
115 HM450k derived CNV 95.65% 
MGMT-STP27 results 
Methylation-specific PCR results 
methylated unmethylated 
Unmethylated 3 13 
methylated 69 29 
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2.3.5 Comparison to existing CNS methylation-based classification 
Nine subsets were formed based on methyl-based biomarker classification (n = 644) and 
the majority of tumors fell into five of the nine subsets (Figure 35A). A subset of gliomas (39/644, 
set 8) with both wild type ATRX and TERTp suggested that alternative mechanisms existed to 
maintain their telomere length. CNS methylation-based classifications are summarized for each 
of the nine subsets (Figure 36A). Discordant samples between the two classification systems 
were described in detail in Figure 36B-E. First row of Figure 36B: 40/644 of all gliomas were 
classified as “CONTR” categories (classified-normal) which are normal brain tissue according to 
CNS methylation-based classification, while the remaining cases were classified into “tumor” 
categories (classified-tumor). The ABSOLUTE tumor purity showed significant differences 
between classified-normal samples and classified-tumor samples in Figure 36C (P < 1´10-5, T-
Test). However, 48 classified-tumor samples also showed tumor purity equal to or less than the 
median tumor purity of classified-normal samples. Second row of Figure 36B: all CONTR, HEMI 
(methylation class control tissue, hemispheric cortex) in subgroups 1 to 4 are expected to be IDH 
wild type and all have been detected with IDH mutation by DNA sequencing. Third row of Figure 
36B: Twelve samples in Grp2 (CONTR, HEMI; A IDH; and A IDH, HG) were classified as either 
normal brain normal tissue or IDH wild type glioma without chr1p19q codel while their CNV profile 
from SNP6 showed clear chr1p19q codel (Figure 36D). Fourth row of Figure 36B: SFT, HMPC 
(methylation class solitary fibrous tumor / hemangiopericytoma) samples are expected to have a 
euploid genome while TCGA-19-5951 in Grp7 showed significant chr10 loss and chr19p and 
chr20 amplification (Figure 36E). Fifth row of Figure 36B: A IDH, HG in Grp8 were expected to 
be IDH mutant by CNS classification but, in fact, were wild type by sequencing. Sixth row: Two 
samples from adult patients (TCGA-06-5858 and TCGA-06-6698) were classified as IHG 
(infantile hemispheric glioma) by CNS methylation-based classification which is typically limited 
to infants. The log-rank test among the five enriched subgroups (Grp 1, 2, 3, 7, and 8) showed 
no significant difference in survival compared to Grp1, Grp2, and Grp3 (Figure 36F and 36G). 
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This indicates all patients with IDH mutant tumors have similar survival time regardless of their 
tumors’ ATRX, TERTp, or chr1p19q status. IDH wild type glioma enriched subsets (Grp7 and 
Grp8), showed significantly worse survival from IDH mutant samples. Moreover, Grp7 
demonstrated poorer survival compared with Grp8, whose samples harbored TERTp mutations, 
indicated the negative prognostic significance of TERTp mutation in the absence of IDH or ATRX 
mutation. Grp7 (75/176, 42.61%) also included a significantly higher percentage (P < 0.01) of 
tumors with MGMT promoter methylation compared to Grp8 (7/39, 17.95%).  
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CNS methylation-based calibrated predicted classes
A IDH(184) A IDH,HG(20) CONTR,HEMI(4)
O IDH(156) CONTR,HEMI(6) A IDH(3) A IDH,HG(3)







GBM,MYCN(1) GBM<RTK II (1) LGG,GG(4)
LGG,MYC(1) LGG,PA PF(2) LGG,PA/GG ST(1)
A IDH,HG(1) ANA,PA(1) CNS,NB,FOXR2(3) IHG(2)
DMG,K27(1) HGNET,BCOR(1) PLEX,PEDB(1) PTPR,B(1)
GBM,MES(71) GBM,RTK II (67) GBM,RTK I (24)
CONTR,HEMI(9) CONTR,INFLAM(1) CONTR,REACT(1)
GBM,RTK III (1) SFT,HMPC (1) SUBEPN,PF(1)
ANA PA(1)
IDH         ATRX        TERTp     chr1p19q     #cases
Grp1        Mutant       Mutant          WT       non-codel       208
Grp2        Mutant          WT          Mutant        codel          168
Grp3        Mutant          WT             WT       non-codel        41
Grp4        Mutant          WT          Mutant    non-codel         7
Grp5        Mutant          WT             WT           codel            3
Grp6        Mutant       Mutant        Mutant    non-codel         1
Grp7            WT           WT          Mutant     non-codel       176
Grp8            WT           WT             WT       non-codel        39
Grp9            WT         Mutant          WT       non-codel        1
Discordant samples
All CONTR samples (40)
Grp1:CONTR,HEMI(4) Grp2:CONTR,HEMI(6)
Grp3:CONTR,HEMI(2) Grp4:CONTR,HEMI(3)
Grp2:CONTR,HEMI(6) A IDH(3) A IDH,HG(3)
Grp7: SFT,HMPC (1)
Grp8: A IDH, HG (1)
Grp9: IHG (2)
Detail information
gliomas classifed as normal brain tissue, tumor purity can’t explain (C)
Classified as normal samples, expected to be IDH wild type,
but identified as IDH mutant samples (A)
Not expect chr1p19q co-del, but CNV profile shown codel (D)
Expect euploidy genome, but shown chr10 del and chr19.20 amp (E)
Classified as IDH mutant category, but identified as IDH wild type (A)














































0             50             100           150            200
Grp1    179               35                   7                    2                    0
Grp2    145               25                   5                    2                    0
Grp3     33                 2                    0                    0                    0
Grp7    160                2                    1                    0                    0
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Figure 36: DNA methyl-based glioma classification.  
A All samples with HM450k data available were classified into nine subgroups according to their 
methyl-based genetic alterations. The number of samples for each subset is also provided. The 
CNS methylation-based calibrated categories are summarized for each subgroup in the rightmost 
column. B By comparing the predicted annotation between both methyl-based and CNS 
methylation-based classification, all discordant samples were picked out with detailed 
information. The left column shows the discordant samples and their subgroup belonging in A. 
The right column shows the rationale why they were discordant samples. C Boxplot showing the 
comparison of ABSOLUTE tumor purity between the samples classified into CONTR categories 
(classified-normal) and samples classified as tumor categories (classified-tumor). Each point 
represents one sample. D SNP6-based CNV profile of the 12 samples in Grp2 (CONTR, HEMI; 
A IDH; A IDH, HG) clearly showing chr1p19q codel. The upper and lower panel show the profiles 
of chr1 and chr19, respectively. E Whole genome CNV profile derived SNP6 array for the sample 
classified as SFT, HMPC in Grp7. F Kaplan-Meier plot with overall survival time (months) for the 
five enriched subgroups in A (Grp1, 2, 3, 7, and 8). The risk table is provided below. G Log-rank 
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Chapter 3 
3 Gene expression subtype prediction 
As I described in the first chapter, gene expression subtypes were identified in GBM which 
classifies GBM into three subgroups: CL, MES, and PN. Samples belong to each subgroup have 
their distinguished genetic characterizations, such as high expressed gene sets, amplified or 
deleted genes in terms of copy number, and mutant genes. Because there are three subtypes, it 
is a multi-class problem to build a predictive model for gene expression subtypes. 
3.1 Methods 
3.1.1 DNA methylation data 
To increase the number of samples available for model building, I included all GBM in 
TCGA with HM27k and HM450k data available. TCGA level 3 data were directly used for samples 
with HM27k data. Samples with HM450k data were processed with UniD pipeline and further 
normalized with BMIQ (66). HM450k probes belong to the following categories were deleted: 
those missing from the EPIC platform, those that were multi-hit (76) or snp-hit (76), those located 
on chromosome X or Y, and those with ³5% missing values in the data set. Then the retained 
HM450k probes were intersected with HM27k probes. Only probes existing in both platforms 
were kept for the following analysis. The retained probes belonging to following categories were 
deleted: (1) those with missing values in ≥5 samples, (2) those not located on CpG island, and 
(3) those not mapped to a known gene. Samples without gene expression data (Agilent 244K) 
were also excluded. For each probe, the Spearman correlation coefficient value was calculated 
between the methylation level and corresponding gene expression level. Probes with an absolute 
correlation coefficient value ≥ 0.1 were included (Figure 37). 
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Figure 37: Data processing of DNA methylation data for gene expression subtype prediction 
 
3.1.2 Gene expression subtypes annotation 
The gene expression subtype and empirical p-value calculated by permutations were 
obtained for each sample according to the published algorithm (9). A probability of each sample 
belonging to each subtype was calculated as shown below (the CL subtype was used as an 
example). This per sample per subtype probability was used to calculate the sum of different 
probabilities, which is one of the metrics to evaluate model performance. 
𝑃𝑟𝑜𝑏¢ =
1 − 𝑃. 𝑣𝑎𝑙𝑢𝑒¢
(1 − 𝑃. 𝑣𝑎𝑙𝑢𝑒¢) + (1 − 𝑃. 𝑣𝑎𝑙𝑢𝑒R) + (1 − 𝑃. 𝑣𝑎𝑙𝑢𝑒¦)
=
1 − 𝑃. 𝑣𝑎𝑙𝑢𝑒¢
3 − (𝑃. 𝑣𝑎𝑙𝑢𝑒¢ + 𝑃. 𝑣𝑎𝑙𝑢𝑒R + 𝑃. 𝑣𝑎𝑙𝑢𝑒¦)
 
3.1.3 Model building 
For gene expression subtype predictions, subtype and probability were calculated using 
gene expression data and were used as a reference for model building (9). Samples were 
randomly stratified into training (60%), development (20%), and test (20%) sets with gene 
expression subtype as the stratification factor. The Fselector (R package) built within the mlr 
Raw Data from 450K (GBM + LGG)
Exclude probes:
  located on Chr X/Y
  Affected by SNP
  Mapped to multi-sites
  Not avail on EPIC array
Set probe as missing value:
  If beadcount <=3
  if detection P>.05
















Data ready to use
GBM raw data (450K) GBM TCGA Level 3 data (27K)
BMIQ normalization. Exclude probes:
Located on Chr X/Y; mapped to multi-sites
Affected by SNP; not avail on EPIC array
Exclude probes NA >=5% 
impute rest NAs
Methylation data
Methylation + gene expression data
Exclude samples without 
gene expression data
intersect probes; combine samples
Exclude probes not on CpG 
island; spearman abs(cor)<0.1
GBM gene expression data
Data ready to use (356 samples 1263 probes)
LGG + GBM samples (450K data + annotation)
Stratified sampliing
Training (60%) Development (20%) Test (20%)
Variable Selection Model Selection
Candidate Models Final model Model Performance
C




6 algorithms Final model
Stratified sampling
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package(90) in R was applied to the training set and three different evaluation metrics were 
calculated: IG, GR, and SU. Probes were ranked by each evaluation metric from high to low. 
Then the rank sum was added up for each probe. Probes were then sorted by the rank sum from 
high to low. The top probes were those that showed up as the most important in terms of their 
response variable. 
With the selected probes, different probe sets were selected based on different quantile 
values (top 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, and 10%) according to 
importance rankings. In total, 21 machine learning algorithms (Table 37) were fitted and 
evaluated in the training set. For each tested algorithm, a training set with different probe sets 
was applied 100 times using 5-fold CV with seeds from 1 to 100. The prediction accuracy and 
sum of different probabilities were calculated for each fold of CV. The prediction accuracy was 
calculated by comparing the predicted gene expression subtype (predicted subtype) and the 
assigned subtypes were obtained from gene expression data (the “real” subtype). The sum of 
different probabilities was calculated by the sum of the square of the different probability of each 
subtype (C: classical, M: mesenchymal, P: proneural), as shown below. For each algorithm and 
each selected probe set, the prediction accuracy and sum of probability difference from 100 times 
of 5-fold CV were summarized.  
𝑑𝑖𝑓𝑓. 𝑝𝑟𝑜𝑏¢ = (𝑟𝑒𝑎𝑙. 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦¢ − 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑. 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦¢)3 
𝑠𝑢𝑚	𝑜𝑓	𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑡	𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠 = 𝑑𝑖𝑓𝑓. 𝑝𝑟𝑜𝑏¢ + 𝑑𝑖𝑓𝑓. 𝑝𝑟𝑜𝑏R + 𝑑𝑖𝑓𝑓. 𝑝𝑟𝑜𝑏¦ 
 Top candidates with the best prediction accuracy and sum of different probabilities in the 
training set were applied to the development set. The final algorithm was selected based on its 
prediction accuracy in the development set (Figure 38). With the final algorithm determined, all 
samples from the training and development sets were used to build the final model. Then the 
final model was applied to the test set to evaluate its performance. 
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3.1.4 Signature analysis 
For signature analysis, the same genomic context comparison in the binary genomic 
alterations were applied for gene expression signature, except for the CpG island relationship 
comparison because all probes were already filtered by CpG island. 
3.1.5 Prediction results analysis 
For gene expression subtype prediction, misclassified samples in the test set (n = 72) 
were regrouped by their transcriptional subtypes and methyl-based predicted subtypes. The 
correctly classified and misclassified samples were compared in terms of CNV and gene 
expression for each transcriptional subtype using the Wilcoxon rank sum test. 
3.1.6 Model validation 
To validate the gene expression subtype prediction, TCGA LGG gene expression 
subtypes were compared between those determined by DNA methyl-based model and those 
obtained directly using gene expression profile (transc-based) (9). Histopathological and 
genomic characteristics were compared between methyl-based and transc-based subtype 
determinations using c-square or Fisher’s exact tests.  
3.2 Results 
3.2.1 Model building 
GBM samples with HM450k data were processed as described above, which left 129 
samples with 407,067 probes. Samples from the HM27k platform included 287 samples with 
23,578 probes. After data integration, there were 416 samples with 20,720 probes available. 
After probe filters, 9,519 probes were kept for correlation evaluation. I only kept the samples with 
gene expression information available, which led to 1,263 probes and 356 samples making up 
the final data set. In the training set, 212 samples were used for probe importance evaluation, 
and 985 probes were assigned zero importance and then were excluded from the analysis. 
According to the sum of rankings of three important metrics, the top 100%, 90%, 80%, 70%, 60%, 
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50%, 40%, 30%, 20%, and 10% of the 278 probes were used for the 21 machine learning 
algorithms (Figure 39). The misclassification rate of each machine learning algorithm and each 
probe set is summarized in Figure 40. The sum of different of probabilities for each machine 
learning algorithm and each probe set is summarized in Figure 41 and 42. In terms of the probe 
sets, it is clear that the prediction accuracy did not affect by the number of probes involved and 
the average sum of different probabilities decreased as the number of probes increased. To 
reach to the best-predicted probability, I used all 278 probes. 
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Figure 39: Comparison of misclassified rate of TCGA gene expression subtype of 5-fold corss 
validation tests using top quantile probes 
For each machine learning algorithms show in the x-axis, two boxplots are shown: the red boxplot 
shows the misclassification rate when building the model with ranodm four-folds of the traning 
data set and the green boxplot show the misclassification rate when applying the model to the 
left one-fold of the traning data set. The y-axis is the averaged misclassification rate among 5-
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fold CV. Figures a to j represent the top 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 
100% probes, respectively. 
 
 
Figure 40: Summarization of the averaged misclassification rate for the 5-fold CV using top 
quantile probes. 
The x-axis shows the twenty-one machine learning algorithms, the y-axis shows the averaged 
misclassification rate. The different colored dots represent the summarized the mean of 
misclassification rate calculated with different probe set. a. The averaged misclassification rate 
of the model building using random four folds data in the training set. b. The averaged 
misclassification rate when applying the model to predict the left one-fold data in the training set. 
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Figure 41: The summarized sum of different probability among twenty-one machine learning 
algorithms using different top quantile probe sets. 
The x-axis show the evaluated algorithms and the y-axis show the sum of different probability. 
Each boxplot represent the summary of the sum of different probability in the test-fold among the 
5-fold CV among hundreds repeated calculations. Figures a to j show the results of top 10%, 
20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100% quantile probe sets, respectively. 
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Figure 42: Summarized averaged sum of different probability among 5-fold CV using different 
top quantile probe sets 
The x-axis represents the twenty-one machine learning algorithms and the y-axis represents the 
averaged sum of different probability. Each colored dot represents the averaged sum of different 
probability using different probe sets. 
 
The gene expression subtype prediction model utilized 278 probes after probe selection. 
Based on the prediction accuracy and sum of different probabilities, six candidate algorithms 
were selected among the 21 machine learning algorithms. Random forest outperformed the other 
five candidate algorithms and was selected as the final algorithm (Table 38). The final random 
forest model was refitted with training (n = 212) and development (n = 72) sets and achieved a 
prediction accuracy of 72.2% (52/72) in the test set. For probes used in predictive models refer 
to the UniD package. 









Algorithm Predicted accuracy averaged sum of different probabilities per sample 
Boosting 68.06% 0.203081 
cvglmnet 70.83% 0.198657 
cforest 70.83% 0.203108 
randomForest 73.61% 0.195134 
randomForestSRC 73.61% 0.197521 
ranger 73.61% 0.195947 
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3.2.2 Predictive signature analysis 
The gene expression subtype prediction signature was enriched in chromosome 18 
(Table 39) and most of the probes were mapped to the 1st Exon (39.95%) and 5’-UTR regions 
(25.8%) (Table 40). Four probes were mapped to the gene suppressor of cytokine signaling 2 
(SOCS2) and three probes were mapped to ERBB2 and retinol binding protein 1 (RBP1). The 
two most significant GOs were correlated with neuron development and differentiation (Table 
41). 





















1 36923 26 0.070% 3.652% 
9.486E-10 
 
2 27711 17 0.061% 3.182% 
3 20279 26 0.128% 6.650% 
4 16241 5 0.031% 1.597% 
5 19398 15 0.077% 4.011% 
6 28392 13 0.046% 2.375% 
7 23237 13 0.056% 2.902% 
8 16401 10 0.061% 3.163% 
9 7783 15 0.193% 9.997% 
10 18784 7 0.037% 1.933% 
11 23487 19 0.081% 4.196% 
12 20018 7 0.035% 1.814% 
13 9794 4 0.041% 2.118% 
14 12234 15 0.123% 6.360% 
15 12402 6 0.048% 2.509% 
16 17917 14 0.078% 4.053% 
17 23237 19 0.082% 4.241% 
18 4939 12 0.243% 12.602% 
19 21429 9 0.042% 2.178% 
20 8823 16 0.181% 9.406% 
21 3507 5 0.143% 7.395% 
22 7074 5 0.071% 3.666% 
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Table 40: Gene structure enrichment for gene expression subtypes signature 
 
Table 41: GO enrichment analysis results for gene expression subtype signature 
 
 
3.2.3 Predictive results analysis 
For the gene expression subtype predictive model, samples in the test set (n = 72) were 
categorized according to methyl-based and transc-based gene expressions subtype (Figure 
43A). Samples discordant between the two methods showed significant differences in copy 
number variation and gene expression level compared to samples with concordant subtypes. I 
examined alterations reported as enriched in specific subtypes in discordant samples to 
determine which classification approach showed the highest association with these characteristic 
alterations (using the Wilcoxon rank sum test) (Figure 43BC). This further supports methyl-
based classification among discordant cases classified as CL by transcription and MES by 


















TSS200 41774 38 0.091% 11.990% 
< 2.2e-16 
TSS1500 55088 54 0.098% 12.920% 
Body 126827 62 0.049% 6.443% 
3'UTR 13641 3 0.022% 2.899% 
5'UTR 33719 66 0.196% 25.799% 
1st Exon 18147 55 0.303% 39.948% 
not 
categorized 90814 0 0.000% 0.000% 
Category Term Count P-Value Benjamini-adjust p-value 
GOTERM_BP_FAT neuron differentiation 24 4.300E-08 6.80E-05 
GOTERM_BP_FAT neuron development 17 2.100E-05 1.60E-02 
GOTERM_BP_FAT behavioral fear response 5 4.400E-05 2.30E-02 
GOTERM_BP_FAT 
behavioral defense 
response 5 4.400E-05 2.30E-02 
GOTERM_BP_FAT fear response 5 1.200E-04 4.70E-02 
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Figure 43: Methylation-based gene expression subtype predictions analysis in test set 
A Confusion matrix of test set (n = 72) based on gene expression subtype of transc-based 
prediction and methyl-based prediction. (L: left; R: Right). B Transc-based CL and methyl-based 
CL samples were compared with transc-based CL and methyl-based MES samples for gene 
expression level (EGFR, NF1) and copy number (CN) segmentation level (EGFR, CDKN2A). For 
all transc-based CL samples, methyl-based MES sample shows lower EGFR expression (the 
estimated difference is 2.56 and 95% CI is -0.17-5.2, p-value = 0.08), lower EGFR amplification 
(the estimated difference is 1.28 and 95% CI is 0.14-2.86, p-value = 0.0056), higher 
CDKN2A/CDKN2B amplification (the estimated difference is -1.83 and 95% CI is -2.64 to -0.55 
p-value = 0.015), and lower NF1 expression level (the estimated difference is 0.44 and 95% CI 
is 0.04 to 0.92, p-value = 0.029) than methyl-based CL samples. C Transc-based MES and 
methyl-based CL samples were compared with transc-based and methyl-based MES samples 
for gene expression level (EGFR) and CN segmentation level (EGFR, CDKN2A). For transc-
based MES samples, methyl-based CL subtype show higher EGFR expression (the estimated 
difference is 1.42 and 95% CI is 0.04 to 3.25, p-value = 0.04), higher EGFR amplification (the 
estimated difference is 0.68 and 95% CI is 0.27 to 2.44, p-value = 1.9´10-4), and lower 
CDKN2A/CDKN2B amplification (the estimated difference is -1.45 and 95% CI is -2.23 to -0.18, 
p-value = 0.02) compared to methyl-based MES samples. 
 
3.2.4 Predictive model validation 
The gene expression subtypes predicted by methyl-based and transc-based algorithms 
demonstrated large differences from the classification results of the PN subtype in TCGA LGG 
samples (Table 42); 422/486 (86.8%) samples were classified as PN in the methyl-based 
subtype and only 228/486 (46.9%) were classified in the transc-based subtype. Histology, 
chr1p19q codel, MGMT methylation status, IDH1, TP53, ATRX, and PTEN mutation all showed 
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(Figure 44, Table 43). However, a significant association of the NF1 mutation was observed only 
in methyl-based subtype. 
Table 42: gene expression subtype validation using TCGA-LGG samples  
 
 
Figure 44: TCGA LGG samples’ gene expression subtype prediction and other genomic 
alteration profiles 
Heatmap of TCGA-LGG samples (n = 486) with gene expression subtypes, histology, chr1p19q 


































































validation data set TCGA-LGG methyl-based subtype 
CL MES PN 
transc-based 
subtype 
CL 21 19 109 
MES 0 24 85 
PN 0 0 228 
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Table 43: Chi-square test between genomic alteration and methyl-based and transc-based 
gene expression for TCGA-LGG samples 
 
 




astrocytoma 10 (58.82%) 28 (75.68%) 111 (31.90%) 
1.09E-06 oligoastrocytoma 5 (29.41%) 3 (8.1%) 91 (26.15%) 
oligodendroglioma 2 (11.76%) 6 (16.22%) 146 (41.95%) 
sum 17 37 348  
transc-based 
subtype 
astrocytoma 52 (41.94%) 51 (54.83%) 46 (24.86%) 
6.63E-11 oligoastrocytoma 39 (31.45%) 26 (27.96%) 34 (18.38%) 
oligodendroglioma 33 (26.61%) 16 (17.20%) 105 (56.76%) 





codel 0 (0%) 1 (2.5%) 144 (38.4%) 
1.85E-09 
non-codel 19 (100%) 39 (97.5%) 231 (61.6%) 
sum 19 40 375  
transc-based 
subtype 
codel 23 (17.04%) 11 (11.11%) 111 (55.50%) 
3.35E-19 
non-codel 112 (82.96%) 88 (88.89%) 89 (44.50%) 




methylated 10 (47.62%) 17 (39.53%) 373 (88.39%) 
6.51E-15 
unmethylated 11 (52.38%) 26 (60.47%) 49 (11.61%) 
sum 21 43 422  
transc-based 
subtype 
methylated 108 (72.48%) 79 (72.48%) 213 (93.42%) 
2.52E-09 
unmethylated 41 (27.52%) 30 (27.52%) 15 (6.58%) 




mutant 0 (0%) 2 (5%) 336 (89.36%) 
3.04E-42 
WT 19 (100%) 38 (95%) 40 (10.64%) 
sum 19 40 376  
transc-based 
subtype 
mutant 88 (64.71%) 69 (70.41%) 181 (90.05%) 
1.60E-08 
WT 48 (35.29%) 29 (29.59%) 20 (9.95%) 




mutant 0 (0%) 0 (0%) 19 (5.05%) 
0.3305438 
WT 19 (100%) 40 (100%) 357 (94.95%) 
sum 19 40 376  
transc-based 
subtype 
mutant 2 (1.47%) 4 (4.08%) 13 (6.47%) 
0.07515979 
WT 134 (98.53%) 94 (95.92%) 188 (93.53%) 




mutant 1 (5.26%) 12 (30%) 11 (2.93%) 
2.16E-07 
WT 18 (94.74%) 28 (70%) 365 (97.07%) 
sum 19 40 376  
transc-based 
subtype 
mutant 10 (7.35%) 8 (8.16%) 6 (2.99%) 
0.07672947 
WT 126 (92.65%) 90 (91.84%) 195 (97.01%) 
sum 136 98 201  






subtype source subgroups CL MSE PN p.value 
mut.TP53^ 
methyl-based subtype 
mutant 0 (0%) 5 (12.5%) 207 (55.05%) 
2.39E-12 
WT 19 (100%) 35 (87.5%) 169 (44.95%) 
sum 19 40 376  
transc-based subtype 
mutant 70 (51.47%) 64 (65.31%) 78 (38.81%) 
6.62E-05 
WT 66 (48.53%) 34 (34.69%) 123 (61.19%) 
sum 136 98 201  
mut.ATRX^ 
methyl-based subtype 
mutant 0 (0%) 2 (5%) 170 (45.21%) 
5.55E-11 
WT 19 (100%) 38 (95%) 206 (54.79%) 
sum 19 40 376  
transc-based subtype 
mutant 54 (39.71%) 53 (54.08%) 65 (32.34%) 
0.001618116 
WT 82 (60.29%) 45 (45.92%) 136 (67.66%) 
sum 136 98 201  
mut.CIC^ 
methyl-based subtype 
mutant 0 (0%) 0 (0%) 94 (25%) 
3.04E-06 
WT 19 (100%) 40 (100%) 282 (75%) 
sum 19 40 376  
transc-based subtype 
mutant 8 (5.88%) 5 (5.01%) 81 (40.30%) 
1.71E-18 
WT 128 (94.12%) 93 (94.90%) 120 (59.70%) 
sum 136 98 201  
mut.PIK3CA^ 
methyl-based subtype 
mutant 2 (10.53%) 6 (15%) 28 (7.45%) 
0.1918081 
WT 17 (89.47%) 34 (85%) 348 (92.55%) 
sum 0 0 376  
transc-based subtype 
mutant 12 (8.82%) 10 (10.20%) 14 (6.97%) 
0.5739994 
WT 124 (91.18%) 88 (89.80%) 187 (93.03%) 
sum 136 98 201  
mut.PIK3R1^ 
methyl-based subtype 
mutant 1 (5.26%) 0 (0%) 18 (4.79%) 
0.3898719 
WT 18 (94.74%) 40 (100%) 358 (95.21%) 
sum 19 40 376  
transc-based subtype 
mutant 5 (3.68%) 2 (2.04%) 12 (5.97%) 
0.3025682 
WT 131 (96.32%) 96 (97.96%) 189 (94.03%) 
sum 136 98 201  
mut.PTEN^ 
methyl-based subtype 
mutant 5 (26.32%) 7 (17.50%) 6 (1.60%) 
1.06E-07 
WT 14 (73.68%) 33 (82.05%) 370 (98.40%) 
sum 19 40 376  
transc-based subtype 
mutant 11 (8.09%) 6 (6.12%) 1 (0.50%) 
0.000303116 
WT 125 (91.91%) 92 (93.88%) 200 (99.50%) 
sum 136 98 201  
mut.RB1^ 
methyl-based subtype 
mutant 0 (0%) 3 (7.50%) 1 (0.27%) 
4.83E-03 
WT 19 (100%) 37 (92.50%) 375 (99.73%) 
sum 19 40 376  
transc-based subtype 
mutant 1 (0.74%) 2 (2.04%) 1 (0.50%) 
0.3576105 
WT 135 (99.26%) 96 (97.96%) 200 (99.50%) 
sum 136 98 201  














mutant 0 (0%) 0 (0%) 35 (9.31%) 
0.04250279 
WT 19 (100%) 40 (100%) 341 (90.69%) 
sum 19 40 376  
transc-based 
subtype 
mutant 5 (3.68%) 5 (5.01%) 25 (12.44%) 
0.007861747 
WT 131 (96.32%) 93 (94.90%) 176 (87.56%) 




mutant 0 (0%) 0 (0%) 36 (9.57%) 
0.03725316 
WT 19 (100%) 40 (100%) 340 (90.43%) 
sum 19 40 376  
transc-based 
subtype 
mutant 4 (2.94%) 2 (2.04%) 30 (14.93%) 
1.40E-05 
WT 132 (97.06%) 96 (97.96%) 171 (85.07%) 




Hemi-del 4 (19.05%) 8 (18.60%) 101 (24.05%) 
3.66E-27 Homo-del 14 (66.67%) 19 (44.19%) 20 (4.76%) 
Low-amp 0 (0%) 2 (4.65%) 7 (1.67%) 
Neutral 3 (14.29%) 14 (32.56%) 292 (69.52%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 32 (21.48%) 25 (22.94%) 56 (3.98%) 
0.000626091 Homo-del 28 (18.79%) 16 (14.68%) 9 (3.98%) 
Low-amp 4 (2.68%) 1 (0.92%) 4 (1.77%) 
Neutral 85 (57.05%) 67 (61.47%) 157 (69.47%) 




Hemi-del 0 (0%) 1 (2.33%) 3 (0.71%) 
4.73E-43 Homo-del 15 (71.43%) 12 (27.91%) 8 (1.90%) 
Low-amp 6 (28.57%) 17 (39.53%) 57 (13.57%) 
Neutral 0 (0%) 13 (30.23%) 352 (83.81%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 1 (0.67%) 1 (0.92%) 2 (0.88%) 
3.25E-07 Homo-del 26 (17.45%) 7 (6.42%) 2 (0.88%) 
Low-amp 26 (17.45%) 22 (20.18%) 32 (14.16%) 
Neutral 96 (64.43%) 79 (72.48%) 190 (84.07%) 
sum 149 109 226  












Hemi-del 0 (0%) 2 (4.65%) 55 (13.10%) 
0.1453379 
Homo-del 0 (0%) 3 (6.98%) 14 (3.33%) 
Low-amp 1 (4.76%) 2 (4.65%) 8 (1.90%) 
Neutral 20 (95.24%) 36 (83.72%) 343 (81.67%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 11 (7.38%) 6 (5.50%) 40 (17.70%) 
0.01534663 
Homo-del 5 (3.36%) 4 (3.67%) 8 (3.54%) 
Low-amp 2 (1.34%) 3 (2.75%) 6 (2.65%) 
Neutral 131 (87.92%) 96 (88.07%) 172 (76.11%) 




Hemi-del 1 (4.76%) 1 (2.33%) 17 (4.05%) 
0.5311001 
Homo-del 1 (4.76%) 0 (0%) 22 (5.24%) 
Low-amp 0 (0%) 5 (11.63%) 39 (9.29%) 
Neutral 19 (90.48%) 37 (86.05%) 342 (81.43%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 8 (5.37%) 2 (1.83%) 9 (3.98%) 
0.1067253 
Homo-del 5 (3.36%) 7 (6.42%) 11 (4.87%) 
Low-amp 11 (7.38%) 17 (15.60%) 16 (7.08%) 
Neutral 125(83.89%) 83 (76.15%) 190 (84.07%) 




Hemi-del 21 (100%) 32 (74.42%) 74 (17.62%) 
5.92E-25 
Homo-del 0 (0%) 0 (0%) 1 (0.24%) 
Low-amp 0 (0%) 0 (0%) 9 (2.14%) 
Neutral 0 (0%) 11 (25.58%) 336 (80.00%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 54 (36.24%) 37 (33.94%) 36 (15.93%) 
0.00039857 
Homo-del 0 (0%) 0 (0%) 1 (0.44%) 
Low-amp 3 (2.01%) 2 (1.83%) 4 (1.77%) 
Neutral 92 (61.74%) 70 (64.22%) 185 (81.86%) 




Hemi-del 1 (4.76%) 1 (2.33%) 52 (12.38%) 
6.37E-05 
high-amp 4 (19.05%) 4 (9.30%) 10 (2.38%) 
Homo-del 0 (0%) 0 (0%) 1 (0.24%) 
Low-amp 1 (4.76%) 5 (11.63%) 11 (2.62%) 
Neutral 15 (71.43%) 33 (76.74%) 346 (82.38%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 19 (12.75%) 16 (14.68%) 19 (8.41%) 
0.1116996 
high-amp 7 (4.70%) 5 (4.59%) 6 (2.65%) 
Homo-del 0 (0%) 0 (0%) 1 (0.44%) 
Low-amp 4 (2.68%) 8 (7.34%) 5 (2.21%) 
Neutral 119 (79.87%) 80 (73.39%) 195 (86.28%) 
sum 149 109 226  
 
 









Hemi-del 1 (4.76%) 1 (2.33%) 60 (14.29%) 
1.07E-06 
high-amp 2 (9.52%) 1 (2.33%) 1 (0.24%) 
Homo-del 0 (0%) 0 (0%) 1 (0.24%) 
Low-amp 1 (4.76%) 5 (11.63%) 7 (1.67%) 
Neutral 17 (80.95%) 36 (83.72%) 351 (83.57%) 
sum 21 43 420  
transc-based 
subtype 
Hemi-del 19 (12.75%) 21 (19.27%) 22 (9.73%) 
0.03638587 
high-amp 3 (2.01%) 0 (0%) 1 (0.44%) 
Homo-del 0 (0%) 0 (0%) 1 (0.44%) 
Low-amp 4 (2.68%) 6 (5.5%) 3 (1.33%) 
Neutral 123 (82.55%) 82 (75.23%) 199 (88.05%) 




hemi-del 0 (0%) 2 (4.65%) 20 (4.76%) 
3.29E-08 
high-amp 0 (0%) 0 (0%) 20 (4.76%) 
low-amp 16 (76.19%) 7 (16.28%) 74 (17.62%) 
neutral 5 (23.81%) 34 (79.07%) 306 (72.86%) 
sum 21 43 420  
transc-based 
subtype 
hemi-del 4 (2.68%) 9 (8.26%) 9 (3.98%) 
0.03295496 
high-amp 6 (4.03%) 3 (2.75%) 11 (4.87%) 
low-amp 33 (22.15%) 11 (10.09%) 53 (23.45%) 
neutral 106 (71.14%) 86 (78.90%) 153 (67.70%) 




hemi-del 0 (0%) 2 (4.65%) 15 (3.57%) 
1.96E-11 
high-amp 5 (23.81%) 4 (9.30%) 5 (1.19%) 
low-amp 4 (19.05%) 7 (16.28%) 19 (4.52%) 
neutral 12 (57.14%) 30 (69.77%) 381 (90.71%) 
sum 21 43 420  
transc-based 
subtype 
hemi-del 2 (1.34%) 3 (2.75%) 12 (5.31%) 
0.07422154 
high-amp 8 (5.37%) 4 (3.67%) 2 (0.88%) 
low-amp 11 (7.38%) 7 (6.42%) 12 (5.31%) 
neutral 128 (85.91%) 95 (87.16%) 200 (88.50%) 




hemi-del 0 (0%) 2 (4.65%) 21 (5.00%) 
0.001437712 
high-amp 0 (0%) 1 (2.33%) 3 (0.71%) 
low-amp 4 (19.05%) 2 (4.65%) 9 (2.14%) 
neutral 17 (80.95%) 38 (88.37%) 387 (92.14%) 
sum 21 43 420  
transc-based 
subtype 
hemi-del 4 (2.68%) 7 (6.42%) 12 (5.31%) 
0.35457 
high-amp 0 (0%) 2 (1.83%) 2 (0.88%) 
low-amp 7 (4.70%) 3 (2.75%) 5 (2.21%) 
neutral 138 (92.62%) 97 (88.99%) 207 (91.59%) 
sum 149 109 226  
Note: m.gene: indicate the mutation status of the gene; cnv.gene: indicate the copy number 
variations of the gene; *: p-value was calculated with c-square test; ^: p-value was calculated 
with fisher exact test 
 




4.1 Discussion of Prediction results 
The results demonstrated that DNA methylation microarray-based classifiers can 
accurately predict and deconvolute somatic genomic alterations in gliomas and show improved 
enrichment for characteristic genomic alterations.  
4.1.1 Binary genomic alteration prediction 
I found that the methyl-based ATRX prediction model identified cases with likely loss of 
function, even those samples were reported as wild type by sequencing. There exists a mutation 
type shift between set 2 (DNA-seq wild type, methyl-based mutant, and with mutation calls by 
reviewing SNV information) and set 4 (DNA-seq mutant, methyl-based wild type): the enriched 
mutations shifted from frameshift indels and in-frame indels to intron, missense and nonsense 
which may not lead to loss of function. The comparison between the mutation status of ATRX, 
IDH, and TERTp and ATRX expression level indicated that the methyl-based prediction model 
more accurately identifies the samples with true ATRX loss of function. It is reasonable to 
speculate that samples in set 3 (DNA-seq wild type, methyl-based mutant, and no mutation calls 
by reviewing SNV information) may be deactivated by some other mechanisms while ATRX 
mutations at the DNA sequencing level of set 4 (DNA-seq mutant, methyl-based wild type) do 
not change the function of the protein. Besides it, we can further explore the functional impact 
score (FIS) (91) for all mutations detected in ATRX mutation samples. This may help us to identify 
the real functional mutations among all detected mutations. 
The low prediction accuracy of TERTp mutation in NOA-04 samples may due to the 
limited locus tested in target-sequencing.  
When I compared the tumor deconvolution based on the mutation status of IDH, ATRX, 
and TERTp, I found that the methyl-based annotations provided more precise genomic 
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characterizations than DNA-seq annotations. For example, the same glioma sets are compared 
in Figure 44 A and B. Three samples in Figure 44A and one sample in Figure 44B show 
mutation status of both ATRX and TERTp which seems functionally redundant. Four samples 
with IDH wild type status were identified as ATRX mutant, which contradicts to current knowledge 
that IDH mutation is prerequisite of the ATRX mutation in Figure 45A; no such samples are 
shown for this condition in Figure 45B. 
 
Figure 45: Gliomas deconvolution by mutation status of IDH, ATRX, and TERTp. 
A: gliomas are stratified by DNA-seq or PCR-seq annotation of IDH, ATRX, and TERTp mutation 
status. B: the same set of gliomas in A are stratified by methyl-based model predicted IDH, ATRX, 
and TERTp mutation status. C: gliomas with HM450k data available are stratified by methyl-
based model predicted IDH, ATRX, and TERTp mutation status. 
 
CBS has been used to derive the CNV profile from HM450k methylation data and was 
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codel in chr1p19q and a threshold needs to be chosen. This is time-consuming and susceptible 
to considerable inter- and intra-observer variability. The methyl-based predictive model may 
better or more rapidly provide an objective determination of CNV status. 
CNS methylation-based classification (14) has shown great value in standardizing and 
clarifying brain tumor diagnoses by reducing the inter-observer variance and by classifying 
tumors previously unclassified by histology. However, this report focused on comprehensive 
CNS tumor classification based on WHO entities and did not focus on specific genomic 
alterations within tumor subtypes, including gliomas. My comparison of CNS methylation-based 
classification and genomic alterations show that it may not properly identify the specific genomic 
alteration subclasses studies in this report. 
4.1.2 Gene expression subtype prediction 
Due to tumor heterogeneity and the uneven distribution of MES subtype samples in the 
external validation data set (CL, 84; MES, 64; PN, 64), the achieved prediction accuracy of gene 
expression subtype by methylation was not as high as the other genomic alterations. However, 
by investigating the misclassified samples, I found that the methyl-based classification better 
aligned with established, characteristic subtype-associated genomic features compared to the 
transc-based classification. For example, the discordant transc-based CL and methyl-based 
MES samples (n = 5) did not show the characteristics of CL subtype samples, including EGFR 
amplification and high expression and CDKN2A deletion. Instead, they harbored characteristics 
of the MES subtype, such as NF1 deletion.  
Because there is no easy way to turn RNA-seq into a clinical assay, the gene expression 
subtype’s clinical meaning has been underestimated. For example, PN gliomas are more 
sensitive to chemo and radiation treatment and NF-silenced gliomas are more sensitive to 
radiation than temozolomide treatment (92). MES gliomas usually are associate with worse 
survival rates and occur in older patients (9). It is worth noting that PN and MES transitions exist 
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during treatment and following recurrence. Overall, with UniD pipeline available, potential 
therapeutic targets in gene expression subtypes should be easily adopted in the future.  
4.2 Research limitation and future direction 
4.2.1 Research limitations 
There are several limitations to my study. First, using DNAseq results as the ATRX 
mutation gold standard may not be the optimal way; IHC may better capture real ATRX deficiency. 
This may explain why samples in NOA-04 (with IHC as the gold standard) show better prediction 
accuracy (92.7%) than in TCGA development (85.16%) and in the test set (90.48%). Second, 
external validation data NOA-04 only include LGG and no GBM. Third, I only validated the UniD 
pipeline in HM450k data, though UniD pipeline can be applied to the EPIC array as well. 
4.2.2 Future direction 
With developed DNA methylation signatures for key genomic alterations in gliomas, it is 
intuitive to come up with the question: what is the relationship between those DNA methylation 
signatures and key genomic alterations. Whether the DNA methylation profile is caused by the 
somatic mutation, or the DNA methylation profile is the marker for specific cancer cell lineage. 
This topic has been discussed more in section 4.4. ATRX and TERTp mutations are the leading 
causations for telomere length maintenance as described in the introduction section. But there 
exist some cancer samples with none of these two mutations or with both of the mutations. Will 
this related to the epigenetic mechanism? Moreover, the DNA methylation signatures between 
ATRX and TERTp mutation show less overlapping, does this indicate the epigenetic 
independency for ATRX and TERTp? 
One future direction of this research could be expanding predictive relationships to other 
genomic features or biomarkers. For example, I am currently building the DNA methylation 
signature for v-Src avian sarcoma viral oncogene homolog (SRC) kinase family activation in 
glioblastoma. SRC is the first discovered human proto-oncogene and is believed to play an 
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important role in maintaining neoplastic phenotype and tumor progression. Dasatinib is a 
multitargeted kinase inhibitor that can inhibit all SRC family kinase (SFK). However, Radiation 
Therapy Oncology Group (RTOG) 0627 clinical trial that evaluated the dasatinib in recurrent 
GBM failed. One potential reason is the SRC inhibitor was not specifically targeted for SFK 
activated patients. As previously discussed related to gene expression subtype, there is no easy 
way to identify the SRC pathway activation status in patients which leads to the non-precision 
medicine. Therefore, if the SRC pathway activation status could be identified using the DNA 
methylation signature, patients could be provided with the drug more specifically and expect 
better prognoses. 
The DNA methylation microarray has many potential benefits with a wide range of 
application. For example, it can be used with FFPE samples. The sample size can easily be 
increased by applying the assay to past stored samples without the worry of a long sample 
collection time. Moreover, once the assay been run, all data can be stored and all future built 
models can be re-applied to the past sample data and further increase the number of sample 
data. Importantly, DNA methylation microarray can be easily standardized in different hospitals 
and labs and once the microarray assay has been verified, all models can be easily verified. 
Another future direction is expanding this idea to other tumor types, not just to gliomas. 
In fact, the model building procedures and methods used in this study are not glioma specific. 
They can be easily used with other tumor types. For example, the hypermethylation phenotype 
CIMP, has also been found in colon cancer and been associated with BRAF mutation. I believe, 
considering all the advantages and promising findings I have discovered with gliomas, DNA 
methylation signature prediction can benefit research into other tumor types as well and will have 
not only research but also clinical implications. 
4.3 Discussion of current research 
DNA methylation’s application in tumor research is rising. It has been used a lot as 
diagnostic and prognostic biomarkers for tumor subtyping and classification. For example, DNA 
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methylation has been used as the main subtyping feature for medulloblastoma (MB) and 
ependymoma. MB has been classified into four different entities according to their DNA 
methylation profiles: WNT, SHH, group3, and group4 (93), while each entity has its special 
transcriptome profiles, somatic mutations, copy number variations, and clinical outcomes. In 
addition, MB has been further divided into three or four subgroups within each of the major 
entities (94) when incorporating the gene expression profiles together with the DNA methylation 
profiles. With better identification tumor subgroups, we can better design the personalized 
treatment for each patient.  
For this section, I would like to introduce two publications related to my project and 
discuss how my project is different from theirs. 
4.3.1 H. Binder et al. 
Paper information: DNA methylation, transcriptome and genetic copy number signatures 
of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. Acta 
neuropathologica communications 7.1 (2019): 59. 
This paper (95) focused on using the gene expression and DNA methylation profile to 
stratify LGG samples. They identified four consensus subtypes of LGG and further characterized 
them in terms of genomic alterations, microenvironment, treatment, and prognosis. The key 
difference between this paper and my research project is that this paper used unsupervised 
learning method while my project used supervised learning method for tumor classification. 
Unsupervised learning methods can provide us a better understanding of the relationship 
between tumor samples with the data provided. This means the learned relationships between 
samples can vary a lot by the methods and data. There is no specific method to test it. The most 
commonly used method to validate unsupervised learning results is to compare the subgroup 
samples for other tumor features. If the identified subgroups also show differences for other tumor 
features, we can have more confidence that those samples are actually belonging to different 
subgroups. Otherwise, the clustering results may not be very useful. In contrast, my study uses 
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supervised learning with known information. For example, we already know that samples can be 
stratified by key somatic mutations and those are used as reference in our supervised learning 
models. 
4.3.2 Y Paul et al. 
Paper information: Paul, Yashna, et al. "DNA methylation signatures for 2016 WHO 
classification subtypes of diffuse gliomas." Clinical epigenetics 9.1 (2017): 32. 
This paper (96) used the Prediction Analysis of Microarray (PAM) method to identify DNA 
methylation signatures which can separate following samples: LGG IDH wild type versus LGG 
IDH mutant; LGG IDH mutant with chr1p19q codel versus LGG IDH mutant with chr1p19q intact; 
and GBM IDH wild type versus GBM IDH mutant samples. Signatures were validated with TCGA 
samples and other independent cohorts. This study aimed to use DNA methylation to mimic the 
2016 WHO CNS classification for gliomas since both IDH mutation and chr1p19q codel are part 
of the diagnostic criteria. 
Though IDH and chr1p19q codel were covered in this paper, my study expanded it to 
more genomic features including ATRX and TERTp mutation, and gene expression subtypes. 
The starting point is different: my study is not focused on re-capture the exiting gliomas 
classification criteria, but is driven by the hypothesis that DNA methylation signatures can reflect 
different cancer cell lineages. Moreover, this study was limited that you need to know whether 
your sample is LGG or GBM at first. In fact, recent studies have shown that there is no clear 
difference of tumor features and patient’s characteristics between the LGG and GBM if with IDH 
mutation. In addition, this paper identified 14 CpG sites, 14 CpG sites, and 13 CpG sites to 
distinguish each sample comparison without providing the predictive models. Without fixed 
predictive models, signatures can hardly be applied for prediction and may suffer from strong 
subjective bias. Though model provided, it is possible that the model cannot be applied due to 
the small sets of CpG sites involved: those probes may not be available due to missing or quality 
issue.  
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4.4 Which came first, the chicken or the egg? 
We already found the strong associations between DNA methylation profiles and somatic 
mutations. Those key somatic mutations can be used to identify subgroups and can potentially 
be used to delineate tumor progression. For example, IDH mutation is believed to be an early-
stage event and all other alterations, such as ATRX or TERTp mutation, and chr1p19q codel, 
happened after it (15). Moreover, IDH mutation can lead to the genome-wide DNA methylation 
profile change (19). Then, the question is, what are the relationships between DNA methylation 
signatures and other somatic alterations? Does DNA methylation profile identify a specific cancer 
lineage and this cancer lineage eventually acquire that mutation? Or the specific DNA 
methylation pattern is caused by specific somatic alteration? 
To understand the relationships between DNA methylation profiles and somatic 
mutation/genomic alterations, we need to understand how the DNA methylation are maintained 
in normal cells and how the DNA methylation has been reprogrammed in cancer cells. 
4.4.1 DNA methylation maintenance 
DNA methyltransferase (DNMT) family are enzymes which can add the methyl group to 
DNA. There are major three types of DNMT in human: DNMT1, DNMT3a and DNMT3b. All 
DNMTs use the S-adenosyl methionine (SAM) as the donor for methyl group. DNMT1 is the most 
abundant methyltransferase. It helps to maintain the global DNA methylation through direct 
interaction with proliferating cell nuclear antigen (PCNA) and ubiquitin-like, containing PHD and 
RING figure domains 1 (UHRF1). DNMT3a and DNMT3b is more involved in the de novo DNA 
methylation mechanism during the cell development. Many other factors are also essential to 
DNA methylation maintenance except the DNMT family, for example, the lysine-specific 
demethylase 1 (LSD1) which can demethylate both H3K4me and H3K9me of histone 3.  
In addition to add methyl group to DNA, it is also important that the existing methyl group 
can be removed from the DNA through passive and active mechanisms. For passive mechanism, 
methyl group lost due to the absence of maintenance mechanism along with the replications. For 
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active mechanism, TET family enzymes get involved to remove or modify the methyl group 
through oxidizing 5-mC to 5-hmC, and further to 5-fC and 5-caC. 
4.4.2 DNA methylation in cancer cell 
The epigenetic mechanism is central to cancer initiation, development, and progression. 
It is common to observe hypomethylation of the cancer genome and oncogenes and 
hypermethylation of tumor repressor genes. The interplay between these two types of genes, 
oncogene and tumor suppressor genes, are essential during cancer initiation. The loss function 
of tumor suppressor genes can be caused in DNA level: gene mutation or loss of heterogeneity; 
epigenetic level: the change of DNA methylation level in the promoter CpG island regions; and 
histone posttranslational modification. Many genes were found to be directly or indirectly 
associated with the DNA methylation and histone modification enzyme (97) (Table 44 and Table 
45). 
Table 44: DNA methylation modifiers in cancer 
 
MBD1/2: methyl-cpg binding domain protein 1 or 2 
TET1/2: TET methylcytosine dioxygenase 1 or 2 
AID: activation-induced cytidine deaminase 
MDS: myelodysplastic syndromes 
Gene Function Tumor Type Alteration 
DNMT1 DNA methyltransferase Colorectal, non-small cell 
lung, pancreatic, gastric, 
breast cancer 
Mutation,overexpression 
DNMT3A DNA methyltransferase MDS, AML Overexpression 
DNMT3B DNA methyltransferase ICF syndrome, SNPs in breast 
and lung adenoma 
Mutation 
MBD1/2 Methyl binding protein Lung and breast cancer Mutation 




TET2 5’ methylcytosine 
hydroxylase 
MDS, AML, glioma Mutation, silencing 
IDH1/2 Isocitrate 
dehydrogenase 
Glioma, AML Mutation 
AID 5’ cytidine deaminase CML Aberration expression 
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ICF syndrome: immunodeficiency-centromeric instability-facial anomalies syndrome 
CML: chronic myelogenous leukemia 
Note: This table is adapted from You, Jueng Soo, and Peter A. Jones. "Cancer genetics and 
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Table 45: Histone modification in cancer 
 
 
Gene Function Tumor Type Alteration 
MLL1/2/3 Histone methyltransferase 
H3K4 
Bladder TCC, ALL, AML, 
non-Hodgkin lymphoma, 




BRD4 Bromodomain containing 4 Nuclear protein in testis, 
midline carcinoma, 




EZH2 Histone methyltransferae 
H3K27 
Breast, prostate, bladder, 
colon, pancreas, liver, 
gastric, uterine tumors, 
melanoma, lymphoma, 





ASXL Enhancer of trithorax and 
polycomb group (EAP) 
Additional sex combs like 1 
MDS, AML, bohring-Opitz 
syndrome 
Mutation 
BMI-1 PRC1 subunit Ovarian, mantle cell 
lymphomas and Merkel 
cell carcinomas 
Overexpression 
G9a Histone methyltransferase 
H3K9 
HCC, cervical, uterine, 















Bladder, breast, kidney, 
lung, pancreas, 
esophagus, colon, uterus, 
brain 
Mutation 
JARID1B/C Histone demethylase 
H3K4/H3K9 








CREBBP Histone acetyltransferase Gastric and colorectal, 
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MLL1/2/3: lysine methyltransferase 2A/2D/2C 
BRD4: bromodomian containing 4 
EZH2: enhancer of Zeste 2 polycomb repressive complex 2 subunit 
ASXL: additional sex combs like 2, transcriptional regulator 
BMI-1: polycomb group RING finger protein 4 
G9a: enchromatic histone lysine methyltransferase 2 
PRMT1/5: protein arginine methyltransferase 1 
LSD1: lysine demethylase 1A 
UTX: lysine demethylase 6A 
JARID1B/C: lysine demethylase 5B 
EP300: histone acetyltransferase P300 
CREBBP: CREB binding protein 
PCAF: lysine acetyltransferase 2B 
HDAC2: hisone deacetylase 2 
SIRT1: NAD-dependent protein deacetylase sirtuin -1 
HDAC5/7A: hisone deacetylase 5 
HCC: hepatocellular carcinoma 
RCCC: renal cell carcinoma 
Note: This table is adapted from You, Jueng Soo, and Peter A. Jones. "Cancer genetics and 
epigenetics: two sides of the same coin?." Cancer cell 22.1 (2012): 9-20 with license ID 1005420-
1. 
 
Epigenetic mechanism plays a key role during the tumor initiation. For example, 
hypermethylation of tumor suppressor gene promoter region are commonly observed in many 
different cancer types, including RB, BRCA1/2, and PTEN. Some DNA repair genes are also 
associated with epigenetic silencing, such as MGMT. In addition, epigenetic silence can facilitate 
the selection of mutations in key signaling pathways (97). For instance, in the ovarian carcinoma, 
mutation frequency is low and large group of genes were silenced through epigenetic mechanism. 
Furthermore, the cytosine methylation can lead to thymine rather than uracil during the hydrolytic 
deamination. Therefore, the resulted T:G mismatch is more difficult to repair. The mechanism of 
this type of point mutation is not fully understood but it may disrupt the gene activity and further 
disrupt the whole epigenetic regulation mechanism.  
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In summary, genetic and epigenetic are not independent mechanisms during the tumor 
initiation and progression, but closely interacted. Until now, no clear evidence shown that the 
ATRX or TERTp mutation can cause the DNA methylation profile changes. However, they still 
hold the potential by changing other key methylation maintenance genes through complex 
pathway. More interestingly, chr1p19q codel may cause the DNA methylation profile change by 
the LOH of key genes located on either chr1p or chr19q.  
4.5 Conclusion 
My classifier demonstrates that DNA methylation signatures accurately predict and 
deconvolute somatic genomic alterations in human gliomas, thus emphasizing the extensive and 
significant relationship between cancer’s epigenetic signatures and somatic genomic alterations. 
Given that all predictors are based on a single experimental platform, the Infinium HM BeadChip 
arrays, the UniD classifier lends itself to the clinical diagnostic setting. The cost of its array, the 
processing time, and tissue requirements are significantly less than individual sequencing, 
immunohistochemistry, and copy number assays (for example, fluorescence in situ hybridization) 
currently used clinically with these tumors. Moreover, the Infinium array is suitable for FFPE 
samples and can be easily adapted for clinical diagnostic tissues. The MGMT-STP27(46) and 
InfiniumPurify (98) assays, which are based on the same array platform, allow for even further 
unification of glioma biomarkers into a single assay. Furthermore, the successful development 
of this DNA methylation-based, infiltrating glioma-specific classifier highlights that methylation-
based tumor classification systems can be easily developed for other tumor types, not only for 
genomic alterations based classification, but for further grading and prognosis, such as for 
breast(53) or lung cancer (99). For predictive model accessibility, I developed an R package 
named UniD for rapid determination of biomarker status in gliomas (available on GitHub). 
I developed and evaluated a DNA methylation microarray-based classifier that accurately 
predicts and deconvolutes somatic genomic alterations in gliomas, shows improved enrichment 
for characteristic genomic alterations and lends itself to clinical diagnostic settings. The array 
  133 
 
cost, processing time, and tissue requirements are significantly less than what is currently used 
clinically in these tumors. Moreover, the Infinium array is suitable for FFPE samples and can be 
easily adapted for clinical diagnostic tissues. 
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